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FOREWORD 
 
This review of the Literature on the Relation between Drug Use, Impaired Driving 
and Traffic Accidents was undertaken for the European Monitoring Centre for Drugs 
and Drug Addiction - EMCDDA, Lisbon. The health consequences of drug use are a 
priority area for the EMCDDA and impaired driving and road traffic accidents linked 
to drugs constitute an important topic on which comprehensive information is lacking.   
 
There is increasing concern across the EU Member States about the role drug use may 
play in traffic accidents. This finds expression in different issues related to driving, 
for example the risks associated with late night driving and ecstasy/amphetamine use 
in dance and night club contexts, the implications for driving of methadone 
maintenance, or the consequences of the increasing levels of cannabis use reported in 
some countries. In a number of Member States a debate on drug testing of drivers, 
comparable to that already existing for alcohol, is gaining momentum.  
 
The literature review addressed inter alia the relationship between different patterns of 
drug consumption, impaired driving and traffic accidents. In addition drug testing 
procedures and associated legislation regarding drug-impaired driving in the different 
EU Member States were described and the issues raised by such testing reviewed.  
The outcomes of the study included a scientific literature review and annotated 
bibliography on the relation between drug use, impaired driving and traffic accidents. 
 
A multidisciplinary approach was considered essential in order to address the wide 
scope of the project. Accordingly a research consortium was formed which included 
scientists with expertise in the areas of drug abuse, psychology, driving behaviour, 
biomedical sciences, transportation and road safety. Additional expertise where 
required was contributed to the project through the Collaboration Network and Local 
Workshop  integral aspects of the methodology developed to achieve the aims of the 
project. 
 
A Work Programme involving six work packages was developed for the project as 
follows  
  
• Workpackage 1:  Elaboration of Methodological Issues in determining the 
relationship between drug consumption, impaired driving and traffic accidents 
 
• Workpackage 2:  Investigation of Experimental and Laboratory Evidence of the 
effects of different drugs on driving skills 
 
• Workpackage 3:  Investigation of Evidence from Field Studies of a relation 
between drug use and traffic accidents 
 
• Workpackage 4:  Description of Drug Testing Procedures in the context of driving 
in the EU, and identification of issues raised by such testing 
 
• Workpackage 5:  Ongoing development of a Collaboration Network 
 
 v
• Workpackage 6:  Fine tuning of the report material at a Local Workshop involving 
members of the Collaboration Network based in Ireland. 
 
 
The project was carried out over the ten month period April 1998 to January 1999. 
 
The literature review, which is the subject of this report, is presented in three main 
chapters.  Chapter 1, based on Workpackage 1, discusses the methodological issues 
which arise in the literature in the area.  Chapter 2, based on Workpackages 2 and 3, 
reviews the epidemiological and experimental evidence on the relation between 
various medicinal and illicit drugs and driving impairment. Chapter 3 outlines the 
situation in the Member States of the European Union regarding drug testing and 
discusses some recent proposals for screening. Workpackages 5 and 6 informed all 
three chapters of the report. 
 
The second main outcome of this study  An Inventory of Literature on the Relation 
between Drug Use, Impaired Driving and Traffic Accidents1  is a compendium of  
annotated references, and is available as a separate report.  The material was  sourced 
from CD-ROM searches, libraries, web pages, professional organisations, government 
offices and individuals.  The literature spans several disciplines including psychology, 
economics, medicine, forensic science, sociology, politics, law, addiction studies and 
transport studies and should be an important resource document for those interested in 
the drugs-driving issue.   
 
We acknowledge gratefully the assistance given to the project by Irish and 
international members of a Collaboration Network which was formed for the project. 
Every effort has been made to reflect the current position of literature in the field in 
the report.  We trust the outcome of the study will be of benefit to the work of the 
EMCDDA and to the community generally. 
                                                 
1   European Monitoring Centre for Drugs and Drug Addiction. An Inventory of Literature on the 
Relation between Drug Use, Impaired Driving and Traffic Accidents. (CT.97.EP.14) Lisbon : 
EMCDDA, February 1999.  
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EXECUTIVE SUMMARY 
 
There is increasing concern across the EU Member States about the role drug use may 
play in traffic accidents. This literature review addresses inter  alia the relationship 
between different patterns of drug consumption, impaired driving and traffic 
accidents. In addition drug testing procedures and associated legislation regarding 
drug-impaired driving in the different EU Member States are described and the issues 
raised by such testing reviewed.  An annotated bibliography on the relation between 
drug use, impaired driving and traffic accidents has been compiled and is available as 
a separate document2. 
 
This report is divided into three main sections. Chapter One covers the 
methodological issues which arise in studying a relationship between drug use and 
driving. Chapter Two discusses experimental and field evidence of a relationship 
between various medicinal, illicit and new synthetic drugs and driving impairment. 
Chapter Three outlines the situation in European Union countries regarding testing for 
drugs and discusses some recent proposals for screening.  Some of the main issues 
and findings emerging from the review are presented in summary form below. 
 
Some of the main issues discussed in Chapter One are as follows: 
 
• Whilst the relationship between alcohol and driving has been the subject of 
intensive research for many years and clear results have emerged, the same is not 
true of other drugs.  
 
Epidemiological studies 
• It often remains unclear whether accidents occur as a direct result of medicinal 
drug consumption per se or as a result of the underlying reasons why the drugs 
were being taken. 
• Data are often presented with no reference to a comparison group (for example, 
the prevalence of drugs in the remainder of the driving population). 
• Drug traces found in crash victims are often mixed with alcohol and/or other 
drugs, hence making it difficult to isolate the effects of a single drug. 
• The fact that drug traces may be discovered in the body does not necessarily imply 
that they were producing impairing effects in the user. 
 
Performance tests 
• Subjects tend to be young, healthy (and non drug-abusing) volunteers, and hence 
unrepresentative of the general driving population.  
• The post drug-administration performance is likely to be different between healthy 
volunteers and real patients/abusers. 
• Testing often occurs soon or immediately after drug administration, hence only 
acute effects are demonstrated when side-effects are greatest. 
                                                 
2  European Monitoring Centre for Drugs and Drug Addiction. An Inventory of Literature on the 
Relation between Drug Use, Impaired Driving and Traffic Accidents. (CT.97.EP.14) Lisbon : 
EMCDDA, February 1999.  
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• Frequent use of small numbers of subjects which may result in a Type 2 error (i.e. 
the non-detection of existing effects and a lack of statistical power). 
• Content validity problems (the extent to which the individual tests actually 
represent facets of real driving). 
• Construct validity of tests: it is not always the case that tests measure what they 
are meant to measure. 
• The development of a reliable and valid battery of powerfully predictive 
performance tests remains as much of a priority now as it has ever done. 
• In addition, well-conceptualised theories and paradigms underpinning models of 
driving behaviour are still lacking and without these any isolated findings remain 
of limited use. 
 
Simulation techniques and ‘real’ driving 
• They are generally inadequate representations of real-life driving. 
• No simulator is capable of representing every aspect of the driving act 
simultaneously. 
• Artificiality of the situation may cause motivational changes which result in 
biased performances. 
• It is generally the case that only the more automatic processes associated with 
driving such as lane positioning and distance negotiation can be studied since it 
would be unethical and dangerous to arrange for situations to be encountered with 
accident or crash potential. 
• Ethical considerations also prevent the administration of high doses of drugs to 
subjects and therefore the results may not reflect the actual amounts used by drug 
abusers.  
 
Models of driving behaviour 
• Several models exist, although most are based on a  hierarchical resources model, 
consisting of three levels:  
− The strategic level (general trip planning, route selection and risk assessment);  
− The tactical level (actual vehicle manoeuvring and involves overtaking, 
distance between vehicles, avoidance of obstacles);  
− The operational level (tracking and adjustment of speed, etc). 
• Recent proposals put forward by the Institute for Human Psychopharmacology in 
the Netherlands (Vermeeren et al, 1993), are cited as a good and comprehensive 
solution to the methodological problems involved in this area. 
 
In Chapter Two, the following conclusions are drawn regarding the weight of 
evidence surrounding the various drugs: 
 
In the case of Alcohol: 
• Field studies have shown that, where involvement in traffic accidents is 
concerned, no drug or drug group has ever been found with a frequency that 
compares to that of alcohol. 
• Most experimental studies have demonstrated impairment on one or several 
performance skills at one or more BAC's (blood alcohol content), with the 
majority of impairments beginning at BACs at or below 0.07g/dl.  
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• Simulator and on-the-road experiments have generally shown alcohol to have 
deleterious effects on a range of driving skills including brake reaction time, 
'collision' frequency, steering responsiveness and lane control, as well as the 
requisite cognitive skills such as risk-taking appreciation, decision making and 
planning. 
• The causal effects of alcohol on impaired driving are well established to the extent 
where it has been possible to enact legislation for the use of alcohol by drivers 
based on a valid classification system. This is not the case for other drugs.  
• The impairing effects of alcohol are generally potentiated by the presence of other 
drugs. 
 
In the case of Methadone: 
• Experimental studies have suggested that, in naive individuals, the effect of acute 
methadone administration is to produce a dose-dependent reduction in reaction 
time, in visual function and in information processing. Significant psychomotor 
impairments are seldom evident when non-naive subjects have been tested 
however. 
• Where new patients on a maintenance programme are concerned, the literature 
suggests that it is advisable to allow a period of up to a month during which they 
should not drive. 
• Field studies have shown that, where body fluids have been examined for drug 
traces, narcotic analgesics [including methadone] have not featured prominently. 
• In general the effects of the opioids are slight when compared to other drugs such 
as benzodiazepines. 
• As is the case with numerous drugs, methadone can potentiate the deleterious 
effects of alcohol. 
• Both experimental and field studies suggest that methadone use does not result in 
sufficient driving impairments to merit users being designated as unfit; 
experimental studies would suggest that this is particularly the case with non-
naïve or experienced users. 
 
In the case of Cannabis: 
• Where experimental studies are concerned, although there is some conflicting 
evidence, cannabis does not seem to significantly impair very basic perceptual 
mechanisms. 
• However cannabis does impair more subtle aspects of perceptual performance 
such as attention and short-term memory, although these are typically observed at 
higher doses. 
• Most experimental studies have used fairly low doses of cannabis and this may 
not reflect the doses ingested by heavy marihuana users. 
• Field studies have demonstrated that cannabis is one of the most prevalent drugs 
discovered in fluid samples taken from drivers. However, assessment of the causal 
role of cannabis in accident occurrence is complicated by the fact that alcohol is 
also present in the majority of samples. 
• When mixed with alcohol, cannabis is much more likely to be a risk factor than 
when consumed alone. 
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In the case of Benzodiazepines: 
• Where experimental results are concerned there is often little consistency, even 
where similar doses are given before similar tasks. The sedating effects of the 
drugs may cause some impairments on psychomotor tests. 
• Field studies reveal that benzodiazepines are the most frequently detected licit 
drugs in all driver populations. 
• Some authors have concluded that using benzodiazepines approximately doubled 
the risk of motor vehicle accidents. In addition, the risk was higher for drivers 
older than sixty-five.  
• In general, combining alcohol with benzodiazepines results in additive impairing 
effects on psychomotor performance. 
• In general, some benzodiazepine tranquillisers may impair driving skills in the 
first few weeks of treatment, but effects may dissipate with continued use. 
 
In the case of Antihistamines: 
• Experimental evidence suggests that peripherally active as opposed to centrally 
active antihistamines are less likely to cause impairing sedative effects. 
• Some antihistamines which are slow to cross the blood brain barrier and thus 
produce tolerance without central effects, such as astemizole, and especially 
terfenadine, are likely to have little detrimental effect on skill performance.  
• The centrally active first generation agents commonly cause greater performance 
decrements as compared with the newer, non-sedating second generation 
antihistamines.  
• Since antihistamines vary in the extent of their impairing effects it is important 
that pharmacists in particular, as well as general practitioners, nurses and the 
public in general, are informed about the necessity of using the less sedating drugs 
available. 
• Where field studies are concerned, antihistamines are seldom suggested as 
causative factors in traffic accidents. When antihistamine traces have been found 
in fluid samples, alcohol is often also present. 
• Although there is some experimental evidence that antihistamines potentiate the 
effects of alcohol, field evidence suggests that alcohol is by far the greater danger. 
• In general, the use of peripherally acting antihistamines is not likely to result in 
impaired driving performance. 
 
In the case of Antidepressants: 
• Experimental investigations suggest that antidepressants can have both beneficial 
and detrimental effects on psychomotor performance. 
• Experimental studies indicate that antidepressants may impair performance in 
healthy subjects taking the drugs for a week or more. 
• Some studies suggest that patients' performance may actually improve as the 
result of the drugs relieving their depressive symptoms; more needs to be known 
about the effects of depression per se on driving abilities.  
• There is no clear picture from field studies regarding the antidepressant levels in 
drivers responsible for accidents compared to the wider driving population. 
• If possible, the less sedating drugs should be prescribed in preference to older 
more sedating drugs such as amitriptyline.  
• There is little research available on the newer, less sedative antidepressants in 
relation to their effects (other than sedation) on psychomotor performance. 
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• The side effects of the most popular antidepressant, fluoxetine, such as nausea and 
insomnia, can themselves effect driving.  
• Where alcohol is combined with antidepressants, especially the more sedative 
ones, the worst impairments are generally seen in the initial phase of treatment 
and diminish after prolonged treatment. Still alcohol is a bigger problem, and the 
effects of severe, untreated depression on driving capacities may be worse than 
the effects of antidepressants. 
 
In the case of Amphetamines: 
• Experimental studies suggest that at lower doses amphetamines have few effects 
on cognitive functioning, but at higher doses risk-taking increases and responses 
become inappropriate. Lower doses may actually result in an enhancement of 
some psychomotor tasks. 
• Field evidence suggests that there is insufficient evidence to specifically implicate 
amphetamine use in traffic accidents, largely due to a lack of controlled studies.  
• Only a few studies have directly examined alcohol-amphetamine interactions and 
the results are somewhat contradictory.  In general, high doses of amphetamine 
are likely to increase the impairing effects of alcohol. 
• In general therefore, there may be subjective positive stimulant effects associated 
with amphetamine use; however these same effects, especially at higher doses, 
could result in personality changes leading to an increased likelihood of impaired 
driving.  
 
In the case of Ecstasy and Other Synthetic Drugs (GHB, Ketamine, PCP, Fentanyl, 
Ephedrine and Phentermine): 
• It is evident from the comparatively sparse literature on MDMA and other 
synthetic drugs and driving that much more research is required in order to 
increase understanding of the impairing effects of this drug. At present, one must 
extrapolate from the few studies available on psychological effects to the driving 
act. 
• In particular, most medical research has concentrated on the short-term effects of 
MDMA and little is known of its consequences following long-term usage. 
• Ecstasy tablets are often comprised of numerous, potentially toxic constituents, 
the combined effects of which are largely unknown. 
• Similarly, there is very little evidence concerning the specific effects of GHB, 
ketamine, PCP, fentanyl and abused diet drugs on driving abilities and in field 
studies they have not been frequently detected.  
• Given the known side-effects of these drugs however and especially given the 
perception-altering effects of some of them, notably PCP and fentanyl, it is likely 
that they constitute a danger where driving is concerned. 
• At present, much more experimental work needs to be carried out in order to 
elucidate the effects of all these drugs on mental and psychomotor performance. 
 
In Chapter Three, the current situation in most EU countries is outlined as regards 
drug testing procedures, and the following general conclusions are drawn: 
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Existing situation in EU countries: 
• All EC Member States have legal provisions for prohibiting driving under the 
influence (DUI) of psychotropic substances besides alcohol in their respective 
Traffic Codes. However there are no specific criteria related to the different types 
of drugs (licit or illicit), extent of drug use, or definition of an influence.  
• Although EC Legislation gives limits for alcohol, no limits are given for drugs. 
• Countries in the European Union have no laws defining illegal blood limits of 
illicit drugs or medicines. At present there is insufficient evidence to define safe 
levels where drugs other than alcohol are concerned. 
• Since 1994, European pharmaceutical package inserts have had to include some 
statement concerning the potential deleterious effects of the drug on driving, 
although it may be some time before this policy is adopted for all types of 
medication . 
 
Drug testing procedures: 
• One possible method of drug testing is to give police forces expert training in 
roadside behavioural evaluation of suspects. Such a scheme has been established 
in the United States and is relatively inexpensive to set up. 
• Standard drug testing of biological fluids generally consists of immunoassay 
screening followed by gas chromatographic-mass spectrometric (GS/MS) 
confirmation conducted on a urine sample.  
• At present there are no roadside drug tests available. Drugwipe devices using 
sweat or saliva samples (Securetec, Ottobrun, Germany) have been developed 
which can test for cannabis, amphetamines, MDMA, methadone, 
benzodiazepines, cocaine, barbiturates and opiates. 
• Several other tests are now available including Triage, Ezscreen, Accupinch, 
Mach IV, Verdict, Biosign and I.D. Block. 
• Newer methods using sweat or saliva samples are potentially preferable because 
they are virtually non-invasive, fast, and easy to execute by non-scientists (e.g. 
police officers). 
• Saliva-testing or "lollipop" technologies (Cozart Bioscience LTD, Oxfordshire) 
can detect cannabis, amphetamines, MDMA, cocaine, benzodiazepines and 
opiates. There is ongoing work concerned with establishing the sensitivity and 
specificity of many of these tests. 
• Although some techniques have been examined which test hair samples, the 
consensus of opinion indicates that they are not reliably effective due to the 
inconsistent relationship between results and recent drug ingestion. 
 
Conclusion: 
• In general it is concluded that, whilst alcohol still remains the biggest problem on 
the roads, the lesser problem posed by other drugs is still important.  However 
much more experimental and epidemiological investigation regarding the impact 
of other drugs is required. 
• Additionally there still remains a need for a reliable and valid battery of 
psychomotor tests which can predict driving impairment. Beyond this, on-site 
drug testing technology must be further developed so as to produce rapid, accurate 
and cost-effective results. Allied to this, there is a need for police officers to be 
trained in drug-related impairment recognition. 
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Chapter One 
Methodological Issues in Determining the Relationship Between 
Drug Consumption, Impaired Driving and Traffic Accidents 
 
 
1.1 Introduction 
It is estimated that at least 10% of all people killed or injured in traffic accidents are 
taking some type of psychotropic substance (medicinal or illicit) and these may be 
contributory factors to the accident (de Gier, 1993). Since 1987 there has been a 
fourfold increase in the number of drivers killed who have been found to have traces 
of illegal drugs in their bodily fluids (AA Report, 1997). To date however, there is 
still little evidence that medicinal drugs are causally related to traffic accidents; the 
percentage of drivers killed and who have traces of medicinal drugs in their systems 
has stayed at about 5% (AA Report, 1997).  
 
This raises the obvious question of the relationship between drug consumption and 
driving impairment. Whilst the relationship between alcohol and driving has been the 
subject of intensive research for many years and clear results have emerged, the same 
is not true of other drugs. In a recent review of the psychological literature over the 
past 25 years on driving behaviour, Sivak (1997) found that out of the relevant 346 
publications, 25% examined alcohol effects and 9% investigated drugs other than 
alcohol. In addition, the main methodological approach adopted in these studies were 
experimental (55%) and survey (12%).  
 
Klebelsberg (1988) assessed the situation thus:  
"The state of current research into the problem of drugs and driving seems to 
have made little progress over the last few years. On the one hand, evidence of 
individual, highly specific drug effects is accumulating, while on the other 
hand, all attempts to make any more generally valid, universal statements 
have met with no success," (p.32).  
 
This chapter will outline the main methods which have been used to investigate the 
putative relationship between drugs and driving impairments, and will describe the 
problems associated with each approach. 
 
 
1.2 Epidemiological Studies 
Epidemiological studies can generally be categorised into five approaches (Hildegard 
and Berghaus, 1998).  
(1)  In the case of reanalyses of blood specimens positive for alcohol, blood 
samples suspected of containing alcohol are additionally screened for both licit and 
illicit drugs, thus allowing a quantification of the extent to which alcohol users also 
use drugs. For example, Augsberger and Rivier (1997) reanalysed samples from DUI 
drivers and found that 15% of those samples contained benzodiazepines. One of the 
central problems with this type of approach is that the presence of the alcohol makes 
it almost impossible to separately assess the effects of the other drugs involved. In 
addition, the population under scrutiny is highly selective and is unlikely to be 
comparable to the wider driving population. 
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(2)  Screening of blood specimens of injured or killed drivers allows an assessment 
to be made of the extent to which drivers involved in accidents were carrying 
medicinal or illegal drugs in their systems. The sample is usually obtained from 
hospitals and spans a particular time period. In general these studies are not able to 
separate samples from drivers responsible for an accident from samples from non-
responsible drivers.  
(3)  In roadside surveys, drivers are stopped at a set place and time and asked to 
submit themselves to a drug test or a questionnaire. As Hildegard and Berghaus 
(1998) point out, such surveys can merely give a general overview of the frequencies 
of intake of substances in drivers. Therefore it is not possible to say anything about 
the performance-impairing risks of particular drugs or dosages. 
(4)  By using retrospective analysis, information can be acquired from drivers who 
were involved or not involved in accidents at some point in their past concerning their 
usage of drugs at the time and subsequently (see for example Smart, 1974). This 
method is one of the poorer ones since it relies on the integrity of the memory of those 
questioned and there is no objective way to verify information or to establish 
causality. 
(5)  Finally, in analysis of drivers at fault, blood samples of drivers responsible for 
an accident can be compared with either a control group of drivers with no accident 
history, or with drivers who were not responsible for an accident. The rationale 
behind this method is that some statement about the likely contributing influence of a 
drug towards an accident can be made if that drug is found more often among drivers 
responsible for an accident than in the other groups. For example, the 
Benzodiazepine/Driving Collaborative Group (1993) found no significant difference 
between a responsible and a non-responsible group of drivers with respect to their 
consumption of benzodiazepines once the effects of alcohol were allowed for. 
Hildegard and Berghaus (1998) conclude that this type of methodology represent the 
best approach, (p.5). 
 
In this area, epidemiological evidence is quite often inadequate when compared to the 
case of alcohol specifically, as it remains unclear whether accidents occur as a direct 
result of drug consumption per se or as a result of the underlying reasons why the 
drugs were being taken in the first place. It may well be the case, for example, that for 
most people taking prescribed drugs, their driving is actually safer due to the 
medication, for example schizophrenic patients taking antipsychotic drugs (Judd, 
1985).  
 
It is necessary therefore to investigate the possible interaction effects between a 
medical condition and the treatment medicine. One fundamental problem with many 
epidemiological studies is that the data are often presented with no reference to a 
comparison group (the prevalence of drugs in the remainder of the driving 
population), thus making interpretation of the results difficult at best. Mason and 
McBay (1984) make the point that, in order for epidemiological studies using fatality 
blood content results to be meaningful, figures need to be compared to (1) drug traces 
in the wider population of drivers, and (2) drivers in non-fatal accidents. It is 
extremely difficult to obtain blood samples from ordinary citizens in either of these 
groups, due to ethical and legal constraints. 
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Epidemiological approaches are primarily concerned with how prevalent a drug is in a 
population, and conversely, how large a proportion of drug users drawn from a 
random sample are involved in traffic accidents. Whether direct toxicological analysis 
or a questionnaire is used, it must be noted that the number of drivers involved in an 
accident (e.g. who were suspected of driving 'under the influence') is much larger than 
the rare cases which one would find if genuine random samples were drawn 
(Klebelsberg, 1988).  
 
A further practical consideration is that it is known that the rate of drug level increase 
is probably more relevant in terms of driving impairment than absolute levels detected 
hours after initial ingestion of a drug (Cosbey, 1986). There is also the problem that 
similar results are found in differing subject/patient cohorts such as suicide attempts 
and the acutely emotionally stressed (Sanders, 1986). In a recent meta-analysis of 
over two hundred epidemiological studies, Hildegard and Berghaus (1998) concluded 
that, a valid estimation of the risk for road safety induced by medicines, based on the 
best methods, is hardly possible at present, (p.1). 
 
 
1.3 Performance Tests 
It is evident that determining the relationship between drug consumption and driving 
impairment is intrinsically fraught with difficulties. Other than epidemiological 
investigations, the other main approach is the experimental one. The standard 
laboratory approach to drug testing is to administer the drug of interest to the subject 
acutely or according to a regimen and subsequently measure performance on a 
behavioural task. These tasks generally include measures of short-term memory, 
tracking ability, decision/reaction time, perception, attention (sustained and divided), 
speed estimation and reactive loading.  
 
Performance tests can be extremely inadequate in predicting real-life driving skills 
however and the standard laboratory tests may frequently be ecologically invalid 
(woefully inadequate, OHanlon, 1988, p.71). Hindmarch (1980), after cataloguing 
a great number of laboratory psychomotor tests including auditory discrimination, 
perceptual learning and motor tests, concluded that as a whole the results could not 
justifiably be generalised to the driving act. A solid, reliable and valid battery of 
powerfully predictive performance tests remains as much of a priority now as it has 
ever done. In addition, well-conceptualised theories and paradigms underpinning 
models of driving behaviour are still lacking and without these any isolated findings 
remain of limited use. This is important because it is often the assumption in 
experimental studies that because one component of driving (e.g. vigilance) is 
impaired, that the driver will consequently be generally impaired because no 
interactions are assumed to occur between task components (Klebelsberg, 1988). 
 
 
1.4 Simulation Techniques and ‘Real’ Driving 
One solution to the thorny issue of performance measurement is to use driving 
simulation tasks. This may include a computer interface, robotics or virtual reality 
applications. Generally simulators can be of two types (Irving, 1988): interactive 
(wherein the driver has control of the speed and the path of the vehicle), and non-
interactive (wherein the driver is only capable of making decisions but cannot actually 
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control the vehicle). Sophisticated as such techniques have become however, they 
remain inadequate representations of real-life driving, especially in the domains of 
visual and vestibular integration. Moskowitz (1985) notes that no simulator is capable 
of representing every aspect of the driving act simultaneously, but only a subset of 
them, depending on the interest of the investigator and the sophistication of the 
technology.  
 
Similar problems are encountered when real driving tests such as closed-circuit 
driving and monitored driving on public highways are used to measure performance, 
especially because of motivational problems: it is a well established psychological 
phenomenon that when a subject is monitored, their performance improves due to 
increased vigilance, often to a level far above the norm (Sanders, 1986). The 
artificiality inherent in these studies may accordingly make the results of limited 
applicability.  
 
Such real on-the-road driving tests additionally often suffer from a lack of 
experimental control which can only exist in the laboratory, and from the previously 
mentioned theoretical gap between the procedures under scrutiny and actual, non-
monitored driving. For example, it is generally the case that only the more automatic 
processes associated with driving such as lane positioning and distance negotiation 
can be studied since it would be unethical and dangerous to arrange for situations to 
be encountered with accident or crash potential. Ethical considerations also prevent 
the administration of high doses of drugs to subjects and therefore the results may not 
reflect the actual amounts used by drug abusers. Ultimately, many facets of driving 
behaviour are unobservable anyhow, a fact which highlights the demand for adequate 
theoretical models of the driving act. 
 
 
1.5 Problems with Experimental Studies 
Leaving aside the aforementioned problems associated with relating the experimental 
tasks to real-life driving, there are several other difficulties and inadequacies 
associated with such an approach.  
 
One deficiency is that subjects tend to be young, healthy (and non drug-abusing) 
volunteers who are unlikely to be representative of the total driving population. The 
effects of a drug on female subjects my be confounded by hormonal changes 
engendered by phase of menstrual cycle, use of oral contraceptives and menopause 
(Dye, 1990). It also means that their post drug administration performance could be 
worse than the performance of real patients who take the medication in order to 
enhance their functioning. Other than this, there are non-trivial task measurement 
difficulties associated with individual differences. It can be problematic for example 
to quantify or operationalise such variables as mental health, motivation, fatigue and 
risk-taking all of which will undoubtedly effect the outcome of a task in addition to 
variables such as drug tolerance and physical fitness.  
 
The influence of circadian rhythms and time of day also need to be taken into account. 
Even if it is possible to demonstrate the relevance of the task to actual driving, the 
real-life driving process is affected by other variables both environmental and 
vehicular as well as personal, which are virtually impossible to control for in the 
laboratory (Landauer, 1986). As regards the actual tasks themselves, the isolated 
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results from a simple task may not be useful in understanding how they are affected in 
a real-life situation where many competing demands may well be in operation.  
 
Furthermore, it is generally the case that testing occurs soon or immediately after drug 
administration. The deficits in task performance therefore reflect the initial action of 
the drug when side-effects are greatest and not the long-term effects which are 
generally beneficial to the patient and when the side-effects have ceased. In contrast, 
some drugs, most notably LSD and MDMA, may have profound effects ('flashbacks') 
long after the drug has been eliminated from the system. Some of the stimulants 
including amphetamines, ecstasy and cocaine produce a sudden fatigue ('crash') after 
their effects have worn off. Such effects are difficult to simulate in the laboratory. 
 
There are problems concerning the doses typically given in experimental situations. 
The dosage might be sub-therapeutic or even identical to the therapeutic dose, but 
ethical and legal problems make it difficult to administer doses greater then the 
recommended one, yet this prevents any understanding of the likely effects of such 
higher doses on the driving act.  It should also be kept in mind that the same dose can 
have different effects in different subjects due to the individual differences already 
referred to. Many studies only report the effects of an acute dosage of a drug, which 
may be irrelevant to the vast number of individuals who have been taking drugs for a 
long duration.  
 
A further problem concerns the conclusions drawn from a typical placebo-controlled 
investigation; if there is no difference between conditions it is not necessarily the case 
that the drug of interest is having no effect, and a second control using a drug known 
to cause impairment would need to be used.  
 
A potentially serious problem results from the frequent use of small numbers of 
subjects. Hence a Type 2 error may occur, i.e. it may be concluded by an author that a 
drug has no impairing effects when in fact it does and this would have been 
determined if a greater number of subjects had been tested and a more reliable series 
of tests had been used. Vermeeren et al (1993) also point out that many studies suffer 
from a misuse of statistical tests, especially where violations of fundamental 
assumptions are concerned (e.g. parametric versus non-parametric tests).  
 
A further issue which often makes it impossible to compare the effects of a drug from 
study to study is that data are generally not normalised or transformed to a common 
scale. Additionally, there are often content validity problems (the extent to which the 
individual tests actually represent facets of real driving). This is where relating tests to 
a model of driving behaviour is important, but in general this is not done. The same 
applies to the construct validity of tests: it is not always the case that tests measure 
what they are meant to measure.  
 
Finally there is the additional problem of test-retest reliability; often authors to not 
state the relevant coefficient for their tests hence it is difficult to know if the same 
subjects would perform similarly on two or more separate occasions. 
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1.6 General Issues 
Unlike the robust finding that there is a causal relationship between alcohol 
consumption and impaired driving, there is inconsistent evidence that other-drug 
blood levels and driving deficits are linked (Moskowitz, 1985). This is especially a 
problem for epidemiological studies.  
 
The issue is further complicated by the fact that it is often impossible in field studies 
to separate legal from illegal drug use, although as Sherwood (1997) points out, 
distinct patterns often emerge when the two can be distinguished to the extent that the 
illicit use of drugs for sheer intoxication purposes could well be a major source of 
traffic accidents. In addition, it is often the case that  drug traces found in crash 
victims are mixed with alcohol, thus making it problematic to discern the true 
contributing factor to the cause of the accident. 
 
At a fundamental level, the fact that drug traces may be discovered in the body does 
not necessarily imply that they were producing effects in the user. This is often true of 
THC, the active metabolite in cannabis, which can be detected in bodily fluids for 
several days after initial use but which would no longer be functional. This is an 
important point especially as, when alcohol is not a factor, one of the most widely 
used drugs in field studies is cannabis.  
 
In contrast, the observable effects of some psychoactive drugs may only be 
recognised once the drug blood level has returned to a very low level after initial 
uptake. A further complication is the multiple use of drugs which may act 
synergistically or antagonistically, hence rendering it difficult to quantify the 
contribution of each drug to behaviour. This is especially relevant to the drug habits in 
the new dance culture where it is common to 'mix and match'. 
 
 
1.7 Models of Driving Behaviour and Effect Models 
This is one of the major areas which has not been properly addressed in the vast 
number of studies on drugs and driving.  Due to the complexity of the driving process, 
it is necessary to base experimental studies on a solid theoretical framework which 
distinguishes the various performance demands involved. Although several models 
exist including general information processing, processing-stage models, trait models, 
threat-avoidance and zero-risk models, (see Rothengatter (1997) for review), one very 
popular, if general model, is based on the classification system of Janssen (1979, cited 
in Sanders, 1986).  
 
This assumes a hierarchical allocation of resources in which three stages are generally 
distinguished: the operational or control level, the tactical or manoeuvring level, and 
the strategic level. The strategic level includes general trip planning, route selection 
and risk assessment. The tactical level deals with actual vehicle manoeuvring and 
involves overtaking, distance between vehicles, avoidance of obstacles, and so forth. 
Finally the operational level includes aspects such as tracking and adjustment of 
speed. It is assumed that the tactical level is particularly resource-demanding in that it 
requires effortful processing and attention. Thus it is comparatively slow and 
inherently flexible. In contrast, the operational level is considered to be an automatic, 
routine process which is fast and relatively inflexible. Through practice, an increasing 
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number of driving processes are expected to operate at the lower, automatic level. It is 
notable that very few studies have been conducted which incorporate their 
performance tasks into such a model. It is consequently unclear at which levels or 
sublevels drugs are having their effect. 
 
Klebelsberg (1988) has suggested that one of the ways forward methodologically is 
the development of models for possible effect mechanisms. He postulates that four 
types of effect need to be differentiated: Type A effects are in the form of direct 
changes in the physiological conditions relating to efficiency, without however the 
subjects noticing and interpreting these effects (e.g. a deceleration of motor activity). 
Type B effects are in the form of direct changes in motivation (e.g. increase in 
subjective efficiency). Type C effects are secondary and in the form of indirect 
changes in motivation which are the result of the subjective interpretation of drug-
induced changes in the physiological preconditions for achievement. Finally Type D 
effects are also secondary and in the form of indirect changes in achievement as a 
result of drug-induced changes in motivation (e.g. deterioration in the quality of 
achievement as a result of drug-induced euphoria).  
 
It can be important in the assessment of a drug's effects for example to distinguish 
between Type A and Type D effects. In addition  Klebelsberg (1988) suggests that it 
is important to distinguish between primary effects of a drug (on the physiological 
level), secondary effects (on the perceptual level), and tertiary effects (on the 
cognitive and emotional levels). Again it is notable that very few studies relate their 
findings to this type of model. 
 
 
1.8 Recent Proposals 
In a recent report by the Institute for Human Psychopharmacology in the Netherlands 
(Vermeeren et al, 1993), thirteen precise methodological guidelines were proposed by 
an international panel of experts for experimental research on medicinal drugs 
affecting driving behaviour. Their recommendations are worth quoting in full as they 
provide an excellent comprehensive survey of the most important methodological 
issues described so far. 
 
1)  Regarding the problems associated with the use of young volunteers and the 
issue of male versus female subjects, it was proposed that:  
"Subjects participating in drugs and driving studies should reflect a cross-section of 
the driving population and the target population of the drug for age and gender. 
Female subjects should provide assurance of reliable birth-control during the trial. 
Medical screening of female subjects should include a pregnancy test before 
beginning the trial. Medical screening of middle aged and elderly subjects should 
include additional blood and urine examinations, and resting ECGs." 
 
2)  Regarding the problems associated with the extensive use of healthy volunteers 
as opposed to real patients, it was proposed that: 
"Healthy volunteers are generally the first choice for subjects. A healthy volunteer 
study should be followed up by a patient study when it is known or strongly suspected 
that healthy volunteers and ambulant patients would experience different drug 
reactions capable of influencing driving performance." 
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3)  Where the issue of doses is concerned it was proposed that: 
"Studies undertaken to demonstrate a new drug's effects on driving or skills related to 
driving for the first time, should involve at least two conditions with the drug's doses 
differing between them. The doses administered should be the lowest and highest to be 
given therapeutically, or in multiples of the therapeutic dose if there is only one. A 
drug should be tested in healthy volunteers in doses of 1x, 2x and 4x the standard 
therapeutic dose to establish a dose-effect curve, given evidence that the drug is well 
tolerated in such cases. A drug should be tested in the healthy elderly to determine its 
effects on driving performance or skills related to driving in sensitive patients." 
 
4)  Regarding duration of treatment it was proposed that: 
"Studies of a particular drug's effect on driving and skills related to driving should 
generally involve multiple dosing lasting at least until the drug's plasma 
concentration has achieved steady-state, or until a therapeutic effect would have 
occurred in patients." 
 
5)  With reference to control groups or conditions it was proposed that: 
"Studies undertaken to determine a drug's effects on driving or skills related to 
driving should generally include the following control conditions: (1) placebo, (2) an 
active control from the same therapeutic class or a verum (i.e. a 'standard' control, 
not necessarily from the same class). Studies including the use of a verum should 
preferably use one of the following: (1) ethanol sufficient to raise blood alcohol 
concentrations to 0.5 or 0.8 mg/ml., (2) diazepam 10mg." 
 
6)  Regarding sample size it was proposed that: 
"The number of subjects employed in studies of drug effects on driving and skills 
related to driving should provide an acceptable balance between probabilities of Type 
1 and Type 2 errors. The sample size in studies of drug effects on driving and skills 
related to driving should be determined by power calculations. In general, 18 or more 
subjects in a crossover design and more than 18/group in a parallel group design are 
deemed necessary for achieving a sufficient degree of statistical power." 
 
7)  Regarding the issues related to the experimental hypothesis it was proposed that: 
"Investigators should state their hypothesis concerning a particular drug's effect on 
performance before applying statistical tests to the data. They should distinguish 
clearly between the following hypotheses: (1) the drug is assumed to have some 
adverse or beneficial effect on performance, (2) the drug is assumed, a priori, to have 
no effect that can influence performance in a practically relevant manner. 
Investigators aiming to demonstrate the presence of a drug effect should set the Type 
1 error probability at p<.05. Results showing a mean drug-placebo difference with a 
lower p-value should be described as showing a significant drug effect. Investigators 
aiming to demonstrate the absence of a drug effect should set the Type 2 error 
probability at p<.10, or lower, by (a) defining a practically relevant mean drug-
placebo difference, (b) performing power calculations, and (c) ensuring that the 
sample size is large enough to achieve that objective. Results that fail to achieve 
significance at the p<.05 level, while p<.10, can then be described as showing no 
practically relevant drug effects." 
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8)  Concerning the selection of statistical tests it was proposed that: 
"Investigators should state the reasons for the selection of statistical tests used to 
analyse the data. Studies determining the effects of a drug on driving performance or 
skills related to driving should employ the most powerful statistical test that can 
rightly be applied. Evidence should always be given to the effect that the tests' 
assumptions are not violated by the data. Investigators should indicate what measures 
they have taken to correct for alpha-inflation." 
 
9)  Regarding content validity it was proposed that: 
"Performance test batteries applied for determining drug effects on driving should 
possess content validity in two dimensions. The test battery as a whole should provide 
measures covering: (1) a representative range of independent mental/behavioural 
functions relevant to driving, (2) as many independent pharmacological effects of the 
drug under study as possible. Studies determining a drug's effects on driving should 
always include a test to measure sedation or drowsiness as one of the drug's possible 
pharmacological effects. Investigators should always give arguments when they don't 
include tests to measure these pharmacological effects. Studies determining a drug's 
effects on driving should always include tests to determine whether the drug affects 
one of the following functions: divided attention or continuous perceptual-motor co-
ordination. Investigators should always give arguments when they don't include tests 
to measures these functions. Besides the functions [previously mentioned], studies 
determining a drug's effects on driving should preferably include tests to measure as 
many as possible of the following mental/behavioural functions: (1) discrete 
responding, (2) speed and accuracy of decision making, (3) vigilance, (4) risk 
avoidance, (5) dynamic visual acuity, and (6) short-term memory." 
 
10)  Where construct validity is concerned it was proposed that: 
"Individual performance tests applied to determining drug effects relevant to driving 
should possess construct validity in two dimensions. The test should be able to 
measure accurately: (1) a specified mental/behavioural response essential for driving, 
and (2) a specified pharmacological effect that could have an adverse effect on 
performance in any situation. Laboratory performance tests used in a categorisation 
procedure should first be validated by correlating drug induced changes in 
performance on the test with changes in actual driving performance." 
 
11)  Concerning test-retest reliability it was proposed that: 
"Studies undertaken to be included in a drug dossier that will be used for 
categorisation or other legal/regulatory affairs pertaining to effects of drugs on 
driving or skills related to driving should possess the following: (1) either a test-retest 
reliability coefficient for raw scores measured in the absence of drug effects of r = or 
>.70, or (2) a test-retest reliability coefficient for drug-placebo change scores of r = 
or >.50 (preferable). Every reliability coefficient should be accompanied by a full 
description of the type of group on which it was determined." 
 
12)  Where the use of a common scale is concerned it was proposed that: 
"The practical goal of standardising behavioural tests for drug screening purposes 
can not be achieved until the performance measures they yield are recorded on a 
common scale. Procedures for accomplishing this exist and should be applied by 
every investigator participating in research aimed at categorising the driving hazards 
of drugs. Investigators should know the population distribution parameters of tests 
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they commonly use. Investigators should share information on population distribution 
parameters of tests they commonly use with other investigators. This can be achieved 
by collecting all placebo data in a central repository, from which these data are 
generally available. Shifts in performance of one population standard deviation, or 
more, relative to placebo or baseline, should always be considered a large and 
relevant change in performance." 
 
13)  Finally, where simulators and on-the-road paradigms are used, the following 
proposal was made: 
"Studies for establishing the driving hazard potential of a particular drug should 
proceed from conventional laboratory testing to sophisticated driving simulators and 
finally actual driving tests as far as they can be safely applied. The final evidence that 
therapeutic doses of the drug in question would be safe or hazardous to a specified 
degree should be based on the combined results of all tests in the programme. Tests 
that are to be included in a test program should be validated before their results are 
used for formal categorisation of drugs as presumably safe, minor, moderately or 
severely impairing. The most important factor in normal daily driving is the frequency 
of incorrect decisions, i.e. at traffic lights, when passing, merging and crossing an 
intersection. Simulator tests intended to determine drugs' effects on normal daily 
driving ability should therefore include tests of reactions to traffic signals, 
compliance with traffic control devices, passing manoeuvres and turning at 
intersections. Closed-course driving tests should involve decision making and 
response to changes in traffic control devices and manoeuvres involving interaction 
with other experimentally controlled vehicles. Over-the-road driving tests must be 
psychometrically sound and realistic, and include combined city and highway driving 
tests wherein fundamental aspects of the driver-vehicle-road interaction (e.g. road 
tracking, speed maintenance, car following, etc.) are objectively measured and 
subjectively rated by an accompanying driving expert." 
 
 
1.9 Conclusion 
Despite the methodological problems outlined in this section it is evident that the 
various approaches, when correctly executed, are the best available at the present 
time. Certainly there are many studies which fulfil most of the criteria described here 
and this is especially true of the more recent investigations. These studies will be 
discussed in this literature review.  
 
In conclusion, any attempts to investigate the relationship between drugs and driving 
should answer as many of the following questions as possible (Starmer, 1985): 
1)  Does the drug have effects which may impair human skills performance? 
2)  If so, what is the nature of the toxic effects which occur? 
3)  Are these effects manifest at therapeutic dosage? 
4)  Do these effects occur in all or only certain individuals? 
5)  What conditions is the drug used to treat? (Can a case be advanced that the driver 
is safer with his medication than without it?) 
6)  Is the drug available only on medical prescription or can it be bought over the 
counter? 
7)  Is the drug used recreationally? 
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8)  Does the drug interact adversely with other drugs or with alcohol? 
9)  To what extent is the drug used by the driving population? 
10)  Can the drug be detected in body fluids? 
11)  How often is the drug detected (or self-reported) in: (a) drivers apprehended by 
police? (b) drivers hospitalised after a crash? (c) autopsy samples from crash 
victims? 
12) Is there reliable information linking plasma concentration with degree of 
impairment? 
13)  Is the drug representative of its class and are alternatives available? 
 
Whilst few studies can lay claim to such comprehensive treatment of the issues 
involved, the foregoing does indicate the requirement for both experimental and 
epidemiological studies to be carried out with reference to each other. The caveats 
outlined here concerning methodological approaches should be kept in mind in the 
following section, which describes the evidence from both experimental and field 
studies of a relationship between a selection of widely-used drugs and driving 
impairment. 
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Chapter Two 
Evidence from Experimental and Field Studies of a Relationship 
between Drug Use, Driving Impairment and Traffic Accidents 
 
 
2.1 Introduction 
In this chapter, evidence will be described from both experimental and 
epidemiological investigations concerning the relationship between drug use and 
driving impairment. Whilst the review cannot possibly cover the literally hundreds of 
studies which have been conducted over the years, it will concentrate on key studies 
and issues which have produced the most valuable data.  
 
In general, studies have been selected which fulfil most of the methodological criteria 
outlined in the previous section. Where more work has been conducted on a particular 
drug (e.g. cannabis) than on another drug (e.g. ecstasy), this will be reflected in the 
number of studies referred to. Similarly, where a drug has been the subject of more 
experimental investigation as opposed to epidemiological analysis (e.g. antihistamine) 
or vice-versa (e.g. amphetamine), this will be reflected in the relative number of 
investigations described.  
 
There is sometimes an overlap in the studies cited where epidemiological studies are 
concerned, so that the same investigation may be used to give information about the 
prevalence of different drugs. The review also represents a reasonably comprehensive 
coverage of international investigations, especially from Europe and America.  
 
The choice of possible drugs to discuss, both licit and illicit, is extremely large. 
Whilst not every drug will be covered, the drugs selected for review (amphetamines 
(including metamphetamines), antidepressants, antihistamines, ecstasy (MDMA) and 
other new synthetic and diet drugs, benzodiazepines (anxiolytics and hypnotics), 
cannabis (THC) and methadone) are representative of both the drugs which have been 
the subject of the most intense research efforts as evidenced by the number of studies 
produced, and of the drugs which are presently of particular concern in regards to 
their potential deleterious effects on driving safety.  
 
This is especially the case with ecstasy. In addition, a brief outline is given of the 
major findings of research on alcohol which have emerged from studies conducted 
over more than half the century. The other drugs will be compared to the particular 
case of alcohol throughout the review. 
 
 
2.2 Alcohol 
It is estimated that alcohol is involved in 19% of injurious accidents and 22% of fatal 
accidents in the European Union (Lillsund, 1998). The American National Highway 
Traffic Safety Administration (1994b) has estimated that 7% of all crashes and 44% 
of fatal crashes in 1993 involved alcohol use. That year approximately 17,500 people 
died and 289,000 were injured in alcohol-related traffic crashes. In 35% of all traffic 
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fatalities (13,984), the deaths had arisen from crashes in which at least one driver or 
nonoccupant had a blood alcohol content (BAC) of 0.10% or greater3.  
 
High as these figures are, they actually represent a reduction compared to previous 
years. In a recent Australian study, Robertson and Drummer (1994) devised a method 
to examine the culpability of a driver in an accident based on the assumption that 
contributory drugs should be over-represented in a 'responsible-for-accident' sample. 
They analysed a sample of 341 driver fatalities for BAC and found alcohol to be over-
represented in the culpable group (p=.001), with the over-representation rising rapidly 
as the BAC rose over 10%. This is a widely replicated finding. 
 
Alcohol is detected in as many as 70% of single-vehicle crashes, but less so in 
multiple-vehicle accidents. Increased BAC's are associated with greater severity of 
injury. Remarkably, where involvement in traffic accidents is concerned, no drug or 
drug group has ever been found with a frequency that compares to that of alcohol 
(Simpson, 1987). 
 
A recent review of the effects of alcohol on driving by Kerr and Hindmarch (1998) 
comprehensively assimilates what the current state of knowledge is. As regards 
measures of performance, typically measured in a laboratory setting, some of the most 
sensitive measures for alcohol impairment include divided attention performance 
(with impairment starting as low as 0.02g/dl), and tracking performance (Simpson, 
1988). Another frequently used measure is that of reaction time, either simple or 
choice (both visual and auditory).  
 
The general conclusion must be that alcohol slows reaction time, especially at 
moderate to low doses. This must be the conclusion despite some reports that modest 
doses (0.5 1g/kg) of alcohol have either little effect on reaction time (Fagan et al, 
1987) or else actually improve it (Palva et al, 1979). As Kerr and Hindmarch (1998) 
point out, such contradictory results can only be expected given the widely 
established large degree of variation in response to alcohol both inter- and intra-
individually.  
 
Further sources of variance are produced by differing experimental measures, 
methods and doses used by investigators in different laboratories. This is a common 
source of contradiction which is endemic in a substantial amount of the literature 
concerning drugs and driving. It may of course be that in common with many other 
drugs, initial acute effects resulting from low doses produce an enhancing effect on 
performance, but this effect deteriorates rapidly after further consumption, especially 
as tasks become increasingly complex. Thus it is often seen in car driving studies 
(simulated or 'real') that drivers who have taken alcohol will concentrate on one aspect 
of the driving repertoire (e.g. staying in lane) to the detriment of other aspects which 
are at least equally important (e.g. speed control). 
 
Simpson (1988), in a review of 177 studies on the issue of alcohol impairment, found 
that 158 had demonstrated impairment on one or several performance skills at one or 
more BAC's (the majority at BAC's at or below 0.07g/dl). Simulator and on-the-road 
                                                 
3 In this section, the measurement units described are taken directly from the original sources. In the 
interests of accuracy, it was thought that this would be preferable to converting the units to a common 
scale. 
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experiments have generally shown alcohol to have deleterious effects on a range of 
driving skills including brake reaction time, 'collision' frequency, steering 
responsiveness and lane control, as well as the requisite cognitive skills such as risk-
taking appreciation, decision making and planning (see Kerr and Hindmarch, 1998 for 
review). 
 
At or below BAC's of 0.05g/100ml, it can generally be said that driving impairments 
will be seen, with the effects becoming more apparent as the BAC increases. 
Certainly by 100 - 150g/100ml, there will be a marked loss of co-ordination and 
perception. 150 - 200g/100ml will be evident as drunkenness, by 200g/100ml, the 
'passing out' stage occurs, and by 300g/100ml, the risk of poisoning is greatly 
increased. Concentrations of over 450/500g/100ml are likely to be fatal as a result of 
respiratory paralysis. The causal effects of alcohol on impaired driving are well 
established (Joscelyn and Donelson, 1978), to the extent where it has been possible to 
enact legislation for the use of alcohol by drivers based on a valid classification 
system (BAC 0.05 - 0.08% = risk curve begins to ascend; BAC > 0.08% = 
considerable risk increase for most drivers; BAC . 0.1% = definite increase in crash 
risk for all drivers; Klebelsberg, 1988). This is not the case for other drugs. In view of 
these figures it is unsurprising that a 'zero-limit' approach is often argued for. 
 
It is also widely established that the impairing effects of alcohol are generally 
potentiated in a synergistic fashion by the presence of other drugs, although some may 
attenuate its effects or have little effect. In general, where sedative drugs such as some 
of the barbiturates and benzodiazepines are concerned, the combined effect with 
alcohol will produce dangerous additive effects. The addition of some, but not all 
antidepressants, antihistamines and stimulants will also vastly impair cognitive and 
psychomotor abilities beyond the single effect of the alcohol. Interestingly, such 
social drugs as caffeine and nicotine could neutralise the impairing effects of alcohol 
(Michel and Battig, 1989), although, as is often the case, there are contradictory 
results and more work needs to be done to clarify this issue. 
 
 
2.3 Methadone 
Methadone has become the drug of choice for the treatment of heroin/morphine 
withdrawal because it mimics many of its actions including its analgesic properties (5 
- 15mg). It has a long half-life (1 to 1.5 days). Individuals on methadone maintenance 
programmes generally take a daily dose of 60 - 80mg (but this can vary from 30 - 
120mg). Its effects are such that heroin or morphine addicts are often able to resume 
normal life, which can include driving cars. Tolerance develops to the extent that if 
heroin abuse is attempted again the dose is usually insufficient to surmount the 
methadone tolerance (Chesher, 1989). 
 
A recent report on drugs, other than alcohol, and driving in the European Union (de 
Gier, 1995), stated that the incidence of known narcotic analgesic abuse among 
drivers in traffic accidents was in Denmark (1993 survey): 4 cases; Spain (1992 
survey): 1.4% of 289 cases; UK (1995 survey): 0.05%; and Italy (1978-1989 survey): 
3.5% of cases. In the UK the number of heroin addicts has increased four-fold 
between 1980 and 1994, and also the proportion of these on methadone maintenance 
has risen from approximately 50% in 1988 to 70% in 1993 (Alberry et al, 1998). 
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2.3.1  Methadone Experimental Studies 
It is known that methadone can have impairing effects on subjective mood and this 
theoretically could lead to performance skill deficits, at least in non-tolerant subjects 
(Chesher, 1989). However this hypothesis is seldom supported. For example, Kelley 
et al (1978) tested thirty methadone-maintenance patients (mean dose 63mg) on tests 
of distance perception, variable reaction time, auditory threshold, attention span, digit 
span and time perception. They found that the cognitive, perceptual and perceptual-
motor capacities of these patients remained relatively stable throughout the duration 
of the experiment, although there was a small, but significant impairment in the 
distance perception test. This however may not be true of distances greater than those 
tested in the laboratory. 
 
Rothenberg et al (1980,a,b) examined the effects of acute doses of methadone (5 or 
10mg) on naive subjects. They found that methadone caused specific impairments in 
smooth pursuit performance, depressing the gain of horizontal tracking movements. 
Although this is of relevance to driving, the effects may alter with increased tolerance 
as would be the case with methadone-maintenance individuals. 
 
Moskowitz and Robinson (1985) investigated the effects of methadone on tracking 
performance, of potential relevance to driving. In one experiment, 12 patients on 
methadone maintenance (60 - 100mg/day) were compared to 12 ex-heroin addicts not 
on maintenance on both a compensatory and a pursuit tracking task. No significant 
differences were found between the groups: both groups exhibited normal 
performance. In order to control for the possibility that subjects had compensated for 
their performance, a further tracking task of increasing difficulty was used with two 
more groups. Again performance was normal in both groups.  
 
These results suggest that methadone users should not be considered 'impaired' in 
their driving abilities. Note how this contrasts with the Rothenberg et al (1980,a,b) 
studies mentioned above. This illustrates the apparent contradictions which often 
appear in the literature due to differences in methodology, dosage rates, and 
experimental design. 
 
In a complementary study, Robinson and Moskowitz (1985) examined methadone 
influence on visual functioning, concentrating on acuity, accommodation, peripheral 
vision and attentional allocation. Fifteen methadone-maintenance patients (60 - 
80mg/day) were compared to a control group of ex-heroin addicts. Both groups were 
found to perform normally, even two hours later when the drug should have reached 
maximum effect. A second experiment tested more specific aspects of skilled 
performance, including visual search rate and rate of information processing. No 
significant differences were found in the visual search rate task or in information 
processing, however the methadone group did require a greater time interval to 
transfer information from immediate to long-term memory. This effect is however 
unlikely to be of significant importance in a real-life driving situation. 
 
Interestingly, methadone has even been shown to improve some aspects of 
performance skills, for example reaction times (Gordon, 1970; Rothenberg et al, 
1977), although this contrasts with other studies (e.g. Moskowitz and Robinson, 
1985). Gordon (1970) in a much-cited study, found that methadone patients actually 
demonstrated shorter reaction times across a series of three tasks compared to 
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appropriate controls. They concluded that this was not due to a faster motor response 
but to faster information processing, stemming perhaps from increased arousal or 
motivation in the methadone users. Subsequently Rothenberg et al (1977) compared 
twelve methadone users (on 20 - 70mg/day) with a naive control group on two tasks, 
(a vigilance task and a reaction time task) which also included an offer of monetary 
reward for good performance to investigate the motivation hypothesis. Subjects were 
tested before and 2.25 hours after placebo, 5, or 10mg methadone. Again they found 
that addicts had faster reaction times and missed fewer responses than controls, even 
after additional doses.  
 
In contrast control subjects demonstrated a dose-dependent slowing of reaction times 
following methadone administration. In the vigilance task, there were no differences 
found between the groups pre-drug administration but in the post-phase the addicts 
improved relative to the pre-phase whereas the opposite was true of control subjects. 
In terms of the hypotheses originally proposed by Gordon (1970), the fact that there 
were no pre-phase differences in the vigilance task implies that the reaction time 
differences cannot be attributed to attentional differences. In addition, motivation is 
unlikely to be the explanation for the faster reaction times in the methadone group 
since the monetary reward was the same for both groups. Although the precise 
explanation for this phenomenon remains unclear, it is likely that it reflects the 
differences between the tolerance of the addict group (therefore the additional doses 
had no effect), and the effects of methadone on the naive controls. 
 
In Germany, it is the case that every drug addict is deemed unfit to drive, including 
those on methadone maintenance. In contrast the weight of experimental evidence 
suggests that impairments among such individuals are only slight. Accordingly, 
Berghaus et al (1993) set out to investigate two issues: (1) can methadone patients be 
considered as a homogeneous group especially with respect to additional drug 
consumption? and (2) what is their performance like on tasks other than vehicle 
handling skills, such as perception of traffic situations, risk-taking, risk cognition, 
complex performance tasks and personality traits?  
 
The authors compared methadone patients with appropriate naive controls on 
personality and risk-taking questionnaires, and tests of short-term memory, tracking, 
decision and reaction behaviour, perception, sustained attention, speed estimation, 
peripheral attention with a simultaneous central task, and reactive loading. They 
found that the methadone patients differed from controls on several personality 
variables, including heightened sensitivity and emotionality, and a poorer degree of 
check on themselves and of accident avoidance. The patients also yielded poorer 
results on all of the psychomotor tests. Many methadone patients had to be excluded 
from this experiment due to their usage of other drugs, therefore the authors 
concluded that methadone users in Germany are not a homogeneous group  they can 
be separated into those who use methadone only and those who combine it with other 
drugs. The outcome of the testing for the remaining patients (i.e. those taking 
methadone only) suggests that they were indeed unfit to drive. The authors explain the 
discrepancy between their results and those from other studies in terms of their patient 
selection procedure in that other studies may have positively selected better 
methadone patients (perhaps stabilised) who would be less likely to differ from 
controls. 
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Interestingly, a similar conclusion has been reached by Staak et al (1993). When they 
compared thirteen methadone-maintenance patients with control subjects, they found 
that the methadone patients were impaired on tests of tracking, short-term memory, 
decision and reaction time, perception, sustained attention, speed estimation, 
peripheral attention and reactive loading. They noted that when six very good 
methodone taking patients were tested, the differences dissipated but that personality 
parameters, as assessed by personality inventories, remained different. They conclude 
that, "driver fitness of the very few optimal patients depends on the amount of the 
personality disorders." However one problem with these studies is that the subjects 
may have either been undergoing detoxification or being maintained on methadone. 
This may account for the discrepancy between these results and those from other 
studies (Alberry et al, 1998). 
 
Berghaus and Friedel (1994) examined ten studies of driving aptitude amongst 
methadone-maintenance patients and concluded that in the majority, patients did not 
differ from controls in measures of psychomotor performance. Again this suggests 
that such maintenance patients, given that they do not ingest other psychoactive drugs, 
should not be considered unfit to drive. A similar conclusion has been reached by 
Kubitzki (1992/3). They gave twenty-two methadone patients doses of methadone 
ranging from 14 to 120mg and compared them to controls on psychomotor tests 
tapping reaction time, cognitive perceptual speed and peripheral perception. He found 
no significant differences between the two groups. 
 
 
2.3.2 Methadone Field Studies 
Starmer (1986) asserts that, where body fluids have been examined for drug traces, 
"narcotic analgesics [including methadone] have not featured prominently," (p.265). 
Reviewing other epidemiological studies of traffic fatalities, he concludes that 
narcotic analgesics have not been found in sufficient numbers to cause concern. For 
example, an early study by Blomberg and Preusser (1974) found no differences 
between methadone patients and control drivers in terms of the frequency of their 
involvement in traffic accidents including those which caused injury or death. 
 
Maddux et al (1977) compared the driving records of 104 former heroin users in 
Texas during one year of heroin use before admission to methadone maintenance, 
with their records during one year after admission while they were being maintained 
on methadone. Whilst they found that the number of convictions for speeding had 
significantly increased from the year on heroin to the year on methadone, there was 
no change in convictions for negligent collision, other moving violations, driving 
without a licence or in number of accidents. However, the frequency with which the 
drivers were involved in accidents was not significantly different from that of all 
Texas licensed drivers. The authors suggest that the increase in speeding convictions 
amongst methadone users may be a function of the possibility that heroin users drive 
more carefully in order to evade arrest. They further conclude that methadone users 
should not be restricted in their driving on the basis of these findings. 
 
Nielsen et al (1989), in a review of the prevalence of analgesics and benzodiazepines 
in traffic accidents, noted that it was a common conclusion that methadone use is only 
dangerous in traffic until the user has become adjusted to a regular dosage. Similarly, 
Christensen et al (1990) analysed 461 records in Denmark. Of the 180 cases in which 
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an accident had occurred, antidepressants and benzodiazepines  were represented 
above the mean, whereas opioids were not. They suggest therefore that opioids do not 
necessarily make driving dangerous (a common hypothesis), unlike the other drugs 
examined. This may be because of increased tolerance for opioids and a compensating 
increase in attention by the users. 
 
In a U.S. National Transportation Safety Board study (1990) of 157 fatal-to-the-driver 
heavy truck crashes, only in one case was a drivers blood found to contain an opiate 
compound, and he also tested positive for chlorpheniramine, one of the 
antihistamines. Budd et al (1989) also found only a single case of opiate consumption 
in a sample of 600 fatally injured drivers in Los Angeles County and stated that this 
was probably a legitimate therapeutic dose. This was found to correlate well with the 
results from four other epidemiological studies from both the USA and Canada. 
 
Augsburger and Rivier (1997) examined the driving records of 641 drivers suspected 
of driving under the influence of drugs (DUID) in Canton de Vaud. They found that 
methadone was present in 10% of samples. However, the majority of all cases 
contained two or more drugs and this was particularly true for the methadone samples. 
 
 
2.3.3  Summary 
In a major report from the Institute for Drugs, Safety and Behaviour in the 
Netherlands (Wolschrijn et al, 1991), two experts rated methadone impairment at a 
dose of 2.5-10mg as 'moderate'. Thus at least some degree of caution is evidently 
warranted where this drug is concerned. Chesher (1989) suggests that the literature 
warrants the following general conclusions: (i) in naive individuals, the effect of acute 
methadone administration is to produce a dose-dependent reduction in reaction time, 
in visual acuity and in information processing; (ii) with new patients on a 
maintenance programme it is advisable to suggest a period of up to a month during 
which they should not drive. Once established on the programme there is insufficient 
evidence to consider them as impaired where driving is concerned; (iii) in general the 
effects of the opioids are slight when compared to other drugs such as 
benzodiazepines.  This may be because the opioids only act upon opioid receptor cells 
which are presumably not as important for motor skills as are the benzodiazepines 
receptor-bearing cells. 
 
In general then the weight of the evidence reviewed suggests that methadone use does 
not result in sufficient driving impairments to merit non-naïve users being designated 
as unfit. However, one gap in the literature on methadone, as Alberry et al (1998) 
note, is that no assessment of the population of methadone patients driving, and their 
frequency of driving, has been made. 
 
 
2.4 Cannabis 
The primary active ingredient of cannabis is THC (delta-9-tetrahydrocannabinol) and, 
depending on dose and the individual, effects can include those of stimulants, 
sedatives, analgesics and hallucinogens. Most often it is inhaled, with the first 
psychological symptoms becoming noticeable after 5 - 10 minutes. Peak effects may 
occur after 30 minutes and the duration of action of one cigarette can be in the region 
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of 2 to 3 hours. Effects are slower if the drug is orally ingested. The issues of 
tolerance, dependency, and side-effects are still disputed, but the most common 
physiological side-effects are cardiovascular and respiratory. Some have suggested a 
link between cannabis use and schizophrenia (WHO Report, 1996) As this section 
will outline, many investigators have found dose-dependent impairments in several 
cognitive and psychomotor skills. The case of cannabis has become even more 
relevant in recent times because of the proposed therapeutic effects of cannabis for 
conditions such as multiple sclerosis and chemotherapy sickness, however a recent 
report by the Royal Pharmaceutical Society of Great Britain (1998) concluded that, 
"the evidence for the medical efficacy of cannabis for all the putative indications is 
based on anecdote, case reports or relatively small studies. [However] overall, the 
body of evidence, although small, points to efficacy of cannabinoids and the need to 
encourage research," (p.9-10). 
 
In a recent report on drugs other than alcohol and driving in the European Union (de 
Gier et al, 1995), it was stated that the incidence of known cannabis abuse among 
drivers involved in traffic accidents was, in Denmark (1993 survey): 1 case; Spain 
(1992 survey): 1.4% of 289 cases; UK (1995 survey): 4.0%; and Italy (1994 survey): 
5.5% of 200 cases. 
 
 
2.4.1  Cannabis Experimental Studies 
Manno et al (1971) examined pursuit tracking performance in twelve subjects who 
were given four levels of THC dosage (0, 5 and 10mg). Pursuit tracking involves 
seeing the object being tracked as well as the tracking mechanism. They found that 
both high and low doses produced performance deficits at all levels of the task 
complexity. However, the task chosen may not necessarily be of absolute relevance to 
car driving. Sharma and Moskowitz (1975) used a compensatory tracking task which 
is probably more relevant to the actual driving process since it involves the subject 
trying to keep a stimulus in a particular place despite the presence of displacing 
movements. They found that subjects taking THC (200mcg/kg) were impaired on this 
task over the entire duration of the experiment. Thus it appears that cannabis, across a 
range of doses and durations, does impair tracking ability. This suggests that it may be 
attentional processes which are primarily effected. 
 
In a simulator study conducted by Rafaelsen et al (1973) using eight subjects 
receiving either 70gm alcohol or 8, 12 and 16mg THC, it was found that both alcohol 
and THC had an effect on latency of response in stopping the 'car when a red light 
occurred. The impairment was especially remarkable at the higher THC doses with 
alcohol producing a midway effect. However THC had no effect on gear changing 
(unlike alcohol). Apparently it was the perceptual aspects of the task which were 
primarily affected. 
 
Kvalseth (1977) investigated simple and complex reaction time in six cannabis users 
at dose levels of 0, 6.5, and between 19.5 and 26.0mg (THC). The subjects had to 
press a button to respond to a variety of presented visual stimuli. It was found that 
THC had no effect on simple reaction time and there was no relationship between 
THC dose level and performance as the complexity and information processing 
demands of the task increased. This finding is fairly robust especially where simple 
reaction time is concerned. For example in another study of the effects of practice on 
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reaction time conducted by Peeke et al (1976), it was found that a practised reaction 
time test was virtually insensitive to THC effects whereas the unpractised version is 
sensitive. They suggest that it is the automatic nature of the well-practised task which 
renders it insensitive to THC effects, whereas it is the attentional demands of the 
unpractised version which is primarily impaired by the drug. This is an opinion also 
shared by Moskowitz (1985). 
 
Smiley et al (1981) used a sophisticated simulator and experimental design with 
thirty-five subjects. They found that cannabis increased variability of velocity and 
position whilst negotiating curves, and of headway and lateral position while 
following curves. There was also a decrease in turn-offs taken in response to traffic 
signs and a reaction time increase to lights requiring responses. Analysis of the 
tracking demands of the task also revealed that cannabis caused more crashes at high 
doses. Similar results have been reported by Dott (1972), and are in general 
agreement with studies which have used real cars for testing (e.g. Attwood et al, 
1980). As such the results imply that cannabis does impair car handling performance, 
although it should be kept in mind that such tasks inherently underestimate the true 
complexities of real-life driving. 
 
Due to the common epidemiological finding that cannabis is often ingested with 
alcohol also present, some studies have examined the interaction between the two 
drugs. For example Chesher et al (1976) gave twelve subjects either a placebo alone, 
cannabis alone (10mg/70kg), alcohol alone (0.54gm/kg) or alcohol plus cannabis. 
They found that the combination of drugs produced impairments in standing 
steadiness, manual dexterity and perceptual speed. However the drugs taken alone had 
little effect. The interaction was considered to be additive. Again this is a common 
finding and points to the fact that ingestion of alcohol and cannabis together produces 
impairments which are greater than the effects of either ingested alone. 
 
In an interesting series of studies conducted by Robbe (1995/96), the effects of 
cannabis on actual driving performance were examined. In the first study, on a road 
closed to other traffic, twenty-four subjects were given either THC 100, 200 or 
300mcg/kg, or placebo. In a 22 kilometre road tracking task (beginning 30 and 90 
minutes after smoking), it was found that their lateral position variability significantly 
increased after each dose relative to placebo in a dose-dependent manner, for up to 
two hours after ingestion. In the second study, (with other traffic present), sixteen 
subjects were given similar doses and performed a 64 kilometre tracking task both 
preceded and followed by car following tasks.  
 
The results were similar to those from the first test, except that the car following was 
only slightly impaired. In the third and final study, (in high-density urban traffic), 
another group of sixteen subjects given either THC 100mcg/kg and placebo, or 
alcohol (mean BAC .034g/%) and placebo, it was found that the alcohol impaired 
performance, but this was not evident to the subjects themselves. In contrast, THC did 
not impair performance yet subjects considered that it had. Robbe concluded that 
THC in single doses up to 300mcg/kg has significant but not dramatic effects on 
driving performance. 
 
Mathias (1996) cites a study by Heishman which aimed at separating the effects of 
alcohol from THC on the functional components of driving. He gave subjects a 
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cannabis cigarette (containing either 0, 1.8 or 3.6% THC) and then another one 10 
minutes later. After 20 minutes it was found that subjects were impaired in their 
ability to stand on one leg for 30 seconds or touch their finger to their nose. Balance 
became much worse where the higher doses were concerned. 
 
Pope et al (1995) reviewed the literature on cannabis and driving looking especially 
for evidence regarding the residual effects of the drug. They found that the data 
support a 'drug residue' effect on attention, psychomotor skills and short-term memory 
during the 12 - 24 hour period immediately after ingestion, but evidence is still 
lacking to support or refute a more prolonged residual effect. In addition, Schmidt et 
al (1995), in a review of 150 simulator and actual driving studies, found that the 
results in general show that cannabis doses between 1, 4 and 22.5mg produced a 
subjective 'high' and that driving impairments were revealed within 2 hours of 
ingestion. However they also note that extended effects have only been found in 
flying simulator tasks wherein the complexity of the tests are very high. 
 
 
2.4.2 Cannabis Field Studies 
Epidemiological studies of alcohol involvement in impaired driving have worked 
because there is an approximately 97% compliance rate with being asked to give a 
breath sample and because these samples are highly correlated with the degree of 
impairment. The same does not hold for epidemiological studies of THC however 
since blood must be sampled and there is typically only a 50-75% compliance rate 
(Moskowitz, 1985). Here we note again that many studies lack an appropriate control 
group. Also, there is little correlation between THC blood concentration and degree of 
impairment largely because psychomotor impairments typically occur one hour after 
smoking when the blood THC content is very low. Therefore a negative THC finding 
does not necessarily indicate that THC was not involved in an accident genesis 
(Moskowitz, 1985). 
 
Reeve (1979) found that 285 (15.9%) blood samples from 1792 Californian drivers 
arrested for impaired driving contained THC greater than 5.0mcg/l, although 111 of 
these also contained alcohol. However the authors do not state how many drivers 
would not give a blood sample but did offer a breath or urine sample, as the law 
allows in California (Moskowitz, 1985). Interpretation is therefore difficult. Mason 
and McBay (1984) heavily criticise this study on methodological grounds and state 
that it is doubtful if it provides any useful data. Smart (1974) examined cannabis 
and accident probability through the use of self-report questionnaires. He found that 
cannabis users have almost as many accidents under its influence as they do when 
under the influence of alcohol. The value of this is limited however because it is 
difficult to show a relationship between cannabis consumption and accidents 
especially as this method relies on the validity of the individual's subjective recall of 
previous events. 
 
Owens et al (1983) examined the blood specimens of 169 dead drivers following 
traffic accidents. They detected no opiate, amphetamine or phencyclidine in any 
specimen, but did find THC (5.9%), barbiturate (5.3%) and cocaine (0.6%), although 
alcohol was also present in the majority of cases. In contrast 66.9% contained ethanol. 
The very low number of cases of drugs other than alcohol lead the authors to 
conclude: "Diverting attention from the many alcohol influenced drivers to the few 
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who might be influenced by other drugs most probably would be counterproductive to 
highway safety," (p.378). This conclusion was repeated by Mason and McBay (1984). 
They analysed blood samples from 600 drivers killed in single-vehicle crashes in 
North Carolina between 1978 and 1981. They again found that ethanol detection was 
far greater (79.3%) than THC (7.8%), methaqualone (6.2%) and barbiturates (3.0%). 
These non-ethanol traces contained concentrations which were within or below 
therapeutic/active ranges. Other drugs were either not detected or only rarely (for 
example no amphetamine traces were found and traces of PCP were rare). Of those 
samples containing drugs, alcohol was also found, and non-alcohol multiple drug use 
was rare. They conclude that, "Ethanol was the only drug tested for that appears to 
have a significantly adverse effect on driving safety," (p.987). This highlights the 
difference between conclusions reached from experimental studies and those from 
field approaches. 
 
McBay and Owens (1981) studied specimens from 100 North Carolina car drivers 
involved in single vehicle crashes. They found THC present in 9 of these, but in 6 of 
these, alcohol was also present. Again because no data concerning THC extent in the 
at-risk population was given, the results may or may not be an overrepresentation of 
the situation. Williams et al (1985), in a survey of 440 young Californian drivers 
killed at the wheel, found that 37% of the sample had THC traceable in their systems. 
The role of cannabis in crash responsibility could not be determined.  
 
A similar finding occurred in a study conducted of 641 drivers conducted by 
Augsberger and Rivier (1996): in the majority of cases two substances were found, 
one of them generally being alcohol, although THC alone was detected in 109 cases. 
However, Warren et al (1981) had previously found that a higher percentage of 
drivers responsible for crashes were found among drivers in whom cannabis was 
present than among drug-free drivers. 
 
In one of the few prospective studies on the subject, Soderstrom et al (1988) 
examined specimens from 1023 vehicular and non-vehicular accidents. They found 
that THC activity of 2ng/ml or more was detected in 34.7% of samples, although there 
was no difference between the two groups. They additionally found that use of 
cannabis and alcohol in combination (16.5%) was highly significant compared with 
cannabis alone (18.3%), alcohol alone (16.1%) or neither drug (49.1%). Alcohol was 
used more than other drugs by the victims of vehicular trauma. 
 
In a U.S. National Transportation Safety Board study (1990) of 164 fatal-to-the-driver 
heavy truck crashes, THC was found to be in the bodies of 21 drivers (12.8%). This 
was identical to the number of cases involving alcohol. Nahas and Latour (1992) in a 
study of 120 blood and urine samples from victims of French traffic accidents, found 
that 14% contained cannabis, 10% benzodiazepines and 1% opiates. Again the highest 
frequency was for alcohol (36%). Heishman (1996) reports that from 6 to 12% of 
non-fatally injured drivers and 4 to 16% of fatally injured drivers had THC in their 
systems. Again it is noted however that most of these samples contained alcohol, 
hence making it difficult to single out the contribution of THC alone. In a U.S. study, 
Brookoff et al (1994) tested 150 samples taken from drivers stopped for reckless 
driving. Of these 13% contained cocaine, 33% cannabis, and 12% both drugs. 
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Recently, in an interim report published by the Department of the Environment in the 
UK (1998), it was found that in a sample of 619 road user fatalities, the drug most 
frequently detected was cannabis, but the usual problems apply when trying to 
estimate the true role of this drug in accident causation. The prevalence of cannabis 
however indicates that there has been a significant increase in the number of users 
killed in traffic accidents. The authors conclude that alcohol is still a much larger 
problem than that represented by drugs. 
 
 
2.4.3  Summary 
Whilst cannabis does not seem to significantly impair basic visual transducing or 
sensory transmission mechanisms, it does impair other aspects of perceptual 
performance such as vigilance tasks and signal detection tasks, although these are 
typically observed at higher doses (Moskowitz, 1985). One thing that is not often 
made clear is whether impairment is maintained for tolerant individuals taking low 
cannabis doses or whether increasing dosage has an additive impairing effect on both 
naive and tolerant users (Alberry, 1998).  
 
Taking both the laboratory and epidemiological evidence together, the conclusion 
reached by the World Health Organisation (1996) is probably justified:  
"There is sufficient consistency and coherence in the evidence from experimental 
studies and studies of cannabinoid levels among accident victims to conclude that 
there is an increased risk of motor vehicle accidents among persons who drive when 
intoxicated with cannabis... This risk is magnified when cannabis is combined with 
intoxicating doses of alcohol …" (p.15). 
 
In summary, the evidence points clearly to the fact that cannabis causes impairments 
in several psychomotor abilities especially tracking, perceptual abilities, vigilance, co-
ordination and driving skills as assessed by both simulator and on-the-road 
methodologies.  However it should be noted that most studies, for obvious reasons, 
have used fairly low doses of cannabis and this may not reflect the doses ingested by 
real cannabis users. Mathias (1996) recommends that future studies should, with 
safety precautions taken, use higher doses. This is of especial relevance in a time 
when cannabis use has increased more than any other drug amongst young people in 
America (1995 Monitoring the Future report cited in Mathias (1996). 
 
 
2.5 Benzodiazepines (Anxiolytics and Hypnotics) 
The benzodiazepines are primarily prescribed for the relief of anxiety, sedation and 
sleep induction and the benefits can generally be sustained for several months. Most, 
if taken at night, show little residual action the following day, unlike some of the 
barbiturates, however these effects vary depending on the particular hypnotic used 
and individual tolerance.  
 
Sometimes diazepam and chlordiazepam are given for the relief of symptoms 
following alcohol withdrawal. The most frequent side-effect is drowsiness, especially 
in the elderly. There is substantial evidence that they produce tolerance, although this 
is sometimes disputed. Severe withdrawal effects are rare. Since there are such a 
variety of benzodiazepines available there are a variety of concomitant 
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pharmacodynamic effects, although generally speaking peak blood plasma levels 
occur from 1 - 8 hours. Half-lives and durations differ depending on the particular 
drug used. Benzodiazepines represent the biggest share of the total world utilisation of 
psychotropic drugs and are the most frequently prescribed minor tranquilliser 
(Ellinwood and Heatherly, 1985). They are also the most frequently detected licit 
drugs in all driver populations (de Gier, 1998). 
 
 
2.5.1  Benzodiazepine Experimental Studies 
There is still a comparative paucity of material related to the illegal use of 
tranquillisers such as the benzodiazepines and their effect on driving skills, although 
work has been done experimentally with healthy volunteers. A common finding is an 
increased sedation and consequent lowering of anxiety after benzodiazepine ingestion. 
This is in turn related to impairments on psychomotor tests, but it is unclear if 
increased risk-taking necessarily ensues as a result. Certainly benzodiazepines are 
over-represented in epidemiological studies of drug-involved traffic accidents (see 
below). 
 
de Gier et al (1981) compared diazepam ingestion (5mg 3x/day) to controls in a 
sample of twenty-two subjects, using both a real driving situation and a laboratory test 
battery including measures of vigilance and simple eye-hand co-ordination (thus 
tapping two opposing attentional states). They found that diazepam subjects were 
impaired in real driving and in the eye-hand co-ordination. They also found no 
relationship between diazepam plasma levels and the measures of performance. 
 
Since many benzodiazepines are known to have a "hangover" effect next morning and 
have been shown to impair certain psychomotor tasks (depending on dose, plasma 
half-life and individual differences), Betts and Birtle (1982) examined the effects of 
temazepam (a short half-life) and flurazepam (a longer half-life). Both drugs impaired 
actual driving performance the next morning in subjects which is particularly 
surprising in the case of temazepam as it is known to cause little psychomotor 
impairment the morning after ingestion. However the authors note that that they 
cannot say whether the effects would wear off or not or if the effect is dose-
dependent. 
 
Harrison and Hindmarch (1985a), compared the residual effects of four drugs (7.5mg 
zopiclone, 1mg lormetazepam, 0.25mg triazolam, 1mg flunitrazepam and placebo) on 
psychomotor performance the morning after ingestion in ten subjects. Zopiclone, 
triazolam and flunitrazepam caused impairments in an information-processing task 
one hour after initial administration. In addition, flunitrazepam impaired reaction time 
on the following morning in the same task. 
 
Laurell and Tornros (1986) investigated the effects of three short-acting 
benzodiazepines (brotizolam (0.25mg), oxazepam (25.0mg) and triazolam (0.25mg)) 
together with nitrazepam (5.0mg) and placebo as controls, on measures derived from 
a simulated 2.5 hour monotonous driving test and a real car emergency avoidance test. 
Motivation was controlled by giving subjects an equal amount of money which could 
be reduced following poor performance. They found that in the acute phase, both 
brotizolam and nitrazepam effected brake reaction times in the monotonous driving 
test relative to placebo whereas the other two drugs did not. In the carry-over phase, 
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no significant differences were found between groups on the same task. In the 
emergency avoidance test, triazolam and nitrazepam caused impairments although the 
differences between groups were not significant. Where oxazepam and nitrazepam 
were concerned in the same test, a slight improvement was noted but again there were 
no significant differences between groups. Thus it would appear that these 
benzodiazepines at low doses have little effect on driving performance. However the 
authors note that results may be different for subjects belonging to high-risk 
categories. 
 
de Gier et al (1986) found that lorazepam (1.0mg three times/day for two weeks) and 
bromazepam (1.5mg three times/day for two weeks) failed to produce impairments in 
either an actual driving test or laboratory tests using actual patients. These 
benzodiazepines have a relatively short elimination half-life compared to, for 
example, diazepam and chlordiazepoxide. 
 
Differing doses of flutoprazepam (2mg and 4mg) on eighteen healthy volunteer 
subjects were analysed for their effects on psychomotor tasks relevant to driving by 
Moser (1990). Two and a half hours after ingestion, only the 4mg dose was seen to 
impair performances, whereas the 2mg dose resulted in only minor skill reductions. 
 
O'Hanlon et al (1995), using patients receiving therapeutic doses of lorazepam, found 
that after two weeks of training on an on-the-road task, patients' lateral driving 
position became very variable despite reported decreases in anxiety. This may not be 
a realistic measure of driving impairment however. More interestingly, the authors 
found that half the patients could not complete the test at the end of the first week 
(whereas all the placebo patients could), but after a further week, only one of the 
lorazepam patients could not complete the test and the lateral position impairment had 
decreased. This study suggests that driving impairments resulting from 
benzodiazepine treatment may only be evident at the start of treatment programmes, 
and may decrease to baseline levels thereafter.  
 
O'Hanlon et al (1995) also compared the effects of diazepam and lorazepam with 
benzodiazepine-like anxiolytics alpidem and suricione and a 5-HT-3 antagonist 
ondansetron on actual driving performance. Although ondansetron had no effect, all 
the others caused a "marked and persuasive" impairment which lasted throughout 
treatment. 
 
Asoh et al (1995) investigated the acute effects of an anxiolytic agent, tandospirone, 
and diazepam on actual driving performance. Twelve subjects were given either a 
placebo, 30mg tandospirone, or 5mg diazepam. Whilst driving continuously for two 
hours at sixty miles per hour, measures of eye movement, steering wheel operation, 
speed variability and sleepiness were taken. Whilst diazepam increased long blinking, 
sleepiness measures, large steering wheel reversals and driving speed reversals, 
tandospirone subjects did not differ from controls. It can therefore be concluded that 
whilst tandospirone does not impair certain aspects of driving, diazepam causes a 
potentially dangerous tendency to fall asleep at the wheel. This steering impairment 
result for diazepam had previously been suggested by Smiley and Moskowitz (1986) 
using simulator technology, although the same task was unaffected by buspirone 
ingestion. 
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In an elaborate study using 145 healthy subjects, Kozena et al (1995) examined the 
effects of diazepam (5mg or 10mg), nitrazepam (5mg), oxazepam (10mg), 
medazepam (10mg) and alprazolam (0.2 or 0.5mg) on a vigilance task (discriminating 
sounds and a visual tracking task). They found that only diazepam (5 and 10mg), 
alprazolam (0.5mg) and nitrazepam (5mg) significantly impaired vigilance and 
required a greater effort to overcome perceived sleepiness. They further noted that 
diazepam had a quicker onset whereas alprazolam effects lasted longer. 
 
 
2.5.2  Benzodiazepine Field Studies 
Using a survey approach, Skegg (1979) found that individuals who had recently used 
drugs, in particular benzodiazepines, were involved in more accidents than others who 
had not been recent drug users. Based on a series of previous epidemiological studies, 
Honkanen et al (1980) suggested that the minimum increment of accident risk induced 
by diazepam to be approximately five times less than that of alcohol. He concluded 
that the evidence indicates that diazepam users in particular are over-represented in 
both injured and fatally injured drivers. 
 
A Danish study of 1382 blood samples taken from drivers stopped for ethanol 
determination (Worm et al, 1985), revealed that 5.5% contained diazepam or 
desmethyldiazepam. The prevalence of diazepam was also noted by Cosbey (1986). 
He analysed 212 drink-driving specimens for drugs taken over a three year period. 
18% of samples contained drugs, and of these the most frequent were 
benzodiazepines (87%), especially diazepam. He notes that diazepam is also the most 
common drug found in surveys conducted in many other countries including New 
Zealand, Australia and Norway. Again, the overall percentage of positive cases is 
quite low, and Cosbey suggests that this may be because the citizens of Northern 
Ireland are more aware of the dangers involved in driving with drugs. 
 
A Norwegian study conducted by Gjerde et al (1988) compared re-arrest rates for fifty 
drunken drivers and fifty drivers with high blood drug concentrations. Of the drugged 
drivers, 32 had high traces of diazepam and 16 were re-arrested inside the following 
three years. The re-arrest rate was low for drivers using amphetamines by contrast. 
For alcohol, the corresponding figure was predictably higher at 20%. The high re-
arrest figure for diazepam users suggests that it may be useful to administer a 
benzodiazepine screening test when such drivers are re-arrested for drunk-driving. 
 
In an examination of 492 cases from a drugs and driving database maintained by the 
Canadian Society of Forensic scientists, Peel and Jeffrey (1990)  found that there were 
relatively few cases of impaired driving due to drug use in Canada. They found that 
the most common drugs involved in impaired driving were THC, diazepam, cocaine 
and codeine, and they tended to be single-drug cases (no alcohol involvement). The 
authors admit that to ascertain the actual involvement of drugs in driving, a study of 
the greater population of Canadian drivers would be necessary. They attribute the low 
number of cases to the fact that Canadian law did not allow for drug testing of 
suspected motorists. 
 
Christopherson et al (1992) examined 1514 samples from suspected drugged drivers 
in Norway. They found that the majority contained benzodiazepines or THC. 
Benzodiazepine doses above the therapeutic level and in combination with other 
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drugs was common. They concluded that benzodiazepines played more of a role in 
Norwegian traffic accidents than THC or amphetamines, although these three are the 
most frequently detected drugs in Norwegian drivers. 
 
In an analysis of 2852 blood samples from accident victims, the 
Benzodiazepine/Driving Collaborative Group (1993) found that 8% contained 
benzodiazepines. When the contribution of alcohol was accounted for, no significant 
difference was found between the 'responsible' and 'non-responsible' groups. The 
authors conclude that alcohol is a much more important risk factor than 
benzodiazepines. In contrast, Currie et al (1995), in a study of 229 blood samples 
from people involved in accidents, found that there was a significantly greater 
representation of tricyclic antidepressants and benzodiazepines present in samples 
taken from 'responsible-for-accident' n = 48) drivers than the corresponding not-
responsible group (n = 15). However the sample size in this study is comparatively 
small, and again no estimates of causality can be made. 
 
In a Swiss study, Ulrich (1994) examined the blood samples of 1000 drivers tested for 
alcohol and found benzodiazepine constituents in 42 cases (primarily valium, 
vegesan, tranxilium, lexotanil and scresta). Thirty five samples also had an alcohol 
level above 0.08%. After further analysis it was decided that benzodiazepine 
concentration was very high in 4 cases, high in 7 cases, moderate in 26 cases and low 
in 10 cases. 
 
In a Canadian study, Mercer and Jeffery (1995) analysed 227 blood sample records 
and concluded that drugs other than alcohol were related to fatal traffic accidents. 
Only 9% of the sample involved drugs only, and of these the most frequent were 
THC, cocaine and diazepam. Although the sample size is very small, the results are 
generally consistent with other studies. 
 
In a Finnish study conducted by Lillsunde et al (1996), they found that 
benzodiazepines were the most frequently found drugs in both 1979 (n = 298; 6%) 
and 1993 (n = 332; 22.9%). No amphetamine traces were found in the earlier study, 
but by 1993 the frequency had increased to 2.7%. No data for THC were available 
earlier, but by 1993 the frequency was 2.4%. However these last two drugs were 
always in combination with others. The authors state that alcohol was responsible for 
impairment in the majority of cases. Although it was evident that drugs other than 
alcohol had increased in Finland, it was not possible in this study to determine the 
effects of each drug on their own. 
 
As can be seen, the results of epidemiological studies examining benzodiazepine 
involvement in road crashes are generally inconsistent. This may reflect the differing 
effects of long- and short-half-life drugs and variations in their duration of use. To 
investigate this issue, Hemmelgarn et al (1997) examined the records of 5579 
Canadian elderly people from 1990 to 1993 and compared them with ten control 
cases. They found that there was an increased rate of crash involvement within the 
first week of long-half-life benzodiazepine use (rate ratio 1.45) whereas the rate ratio 
for continuous use of longer duration up to one year was lower but still significant 
(1.26). In contrast to this, there was no increased risk after the initiation of treatment 
with short-half-life benzodiazepines (1.04) or after continued use (0.91). They 
conclude that, whilst there is no elevated risk for short-half-life benzodiazepines, 
 28
there is an increased risk for traffic accidents with brief or extended exposure to long-
half-life benzodiazepines. 
 
 
2.5.3  Summary 
Where experimental results are concerned there is little consistency, even where 
similar doses are given before similar tasks (Friedel and Staak, 1992).  Studies clearly 
reveal that drug-plasma level is not convincingly correlated with psychomotor/driving 
impairment. Factors such as acute peak levels and tolerance, chronic tolerance and 
individual differences need to be taken into account.  
 
There is an argument that compared to the impairing effects of other drugs which are 
used as minor tranquillizers, benzodiazepines are generally safer (Ellinwood and 
Heatherly, 1985).   However, to add a cautionary note, in a Medline search from 1980 
to 1997 of the relation between benzodiazepine use and traffic accidents, Thomas 
(1998) concluded that using benzodiazepines approximately doubled the risk of motor 
vehicle accidents.  In addition, the risk was higher for drivers over age sixty-five 
when they took longer-acting and greater quantities of the drug.  
 
 
 
Table 1:  Ratings for acute effects 
 
Drug Dosage (mg) Impairment Rating 
Alprazolam 0.25 / 0.5 minor 
 1.0 moderate/not severe 
Bromazepam 1.5 minor 
 3.0/6.0 moderate/not severe 
 12.0 severe 
Brotizolam 0.125/0.25 not severe 
Chlordiazepoxide 5.0/10.0/20.0-25.0 moderate/not severe 
Diazepam 2.0/5.0 moderate 
 10.0/20.0 not severe/severe 
Flunitrazepam 0.5/2.0 severe 
Flurazepam 15.0/30.0 severe 
Lorazepam 0.5/1.0 not severe 
 2.5/5.0 severe 
Lormetazepam 0.5/1.0 moderate/not severe 
 2.0 severe 
Medazepam 5.0/10.0 minor/moderate 
 15.0 severe 
Nitrazepam 2.5/5.0 moderate/not severe 
 10.0 severe 
Oxazepam 10.0/20.0 moderate/not severe 
 30.0/50.0 severe 
Temazepam 5.0/10.0 moderate 
 20.0/30.0 severe 
Triazolam 0.125/0.25 moderate/not severe 
 0.5 severe 
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Table 2:  Ratings for residual effects  
Drug Dosage (mg) Time 
(hrs) 
Impairment Rating 
Brotizolam 0.125/0.25/0.5 22 minor/none 
Diazepam 10.0/15.0/20.0 12 not severe 
  22 moderate/not severe 
Flunitrazepam 0.5/1.0/2.5 12 not severe 
  22 moderate/not severe 
Flurazepam 15.0 12 not severe 
  22 moderate/not severe 
 30 12 severe 
  22 moderate/not severe 
Lorazepam 1.0 12 minor 
  22 moderate/not severe 
 2.5/5.0 12 severe 
  22 moderate/not severe 
Lormetazepam 0.5/2.0 12 none/minor 
  22 minor/moderate 
Nitrazepam 2.5/5.0 12 minor 
  22 minor/moderate 
 10.0 12 not severe 
  22 moderate/not severe 
Oxazepam 10.0 12 minor 
  22 none 
 20.0 22 minor 
 30.0 12 moderate/not severe 
  22 none/minor 
 50.0 12 moderate/not severe 
  22 minor 
Temazepam 10.0/30.0 12 minor 
  22 none/minor 
Triazolam 0.125/0.25 12 minor 
  22 none 
 0.5 12 moderate/not severe 
  22 moderate/not severe 
    
 
 
 
 
Sherwood (1997) tentatively concludes that some benzodiazepines tranquillisers may 
impair driving skills in the first few weeks of treatment, but that these effects may 
dissipate with continued use. 
 
In a major report from the Institute for Drugs, Safety and Behaviour in the 
Netherlands (Wolschrijn et al, 1991), the mean impairment ratings shown in Tables 1 
and 2 were given for most of the benzodiazepines referred to in this review (refer to 
reference for ratings on all other benzodiazepines). 
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2.6 Antihistamines 
Antihistamines are generally prescribed for the treatment of allergic states such as hay 
fever and sometimes as hypnotics. There are two main types: H1-receptor antagonists 
and H2-receptor antagonists. Generally the older antihistamines produce sedative 
effects and consequent impairments on some cognitive and psychomotor tests. These 
effects result from the drugs' impairment of central nervous function which in turn are 
a consequence of their ability to cross the blood-brain barrier. However the newer 
drugs (e.g. astemizole and terfenadine) tend to be largely free of these effects and tend 
to act on peripheral rather than central receptors. Users of antihistamines, especially 
when they are bought over-the-counter, are generally free to engage in everyday 
activities, including the operation of machinery and driving. In 1988, an estimated 30 
million Americans spent more than $500 million for single-entity antihistamine 
(Meltzer, 1990). 
 
 
2.6.1  Antihistamine Experimental Studies 
Nicholson (1979) compared the effects of sustained release formulations of 
antihistamines which are less likely to cause daytime sedation if used overnight. 
Using female subjects, they found that triprolidine hydrochloride (2.5mg) had an 
immediate effect on visuomotor co-ordination persisting for 3 hours, whereas a 10mg 
sustained release form reduced performance only between 1.5 and 5 hours. 
Brompheniramine maleate (4mg) was found to decrease performance between 1.5 and 
3 hours, but the sustained release form (12mg) resulted in impairments only around 
1.5 hours. For both drugs, recovery appeared within a few hours. 
 
Nicholson and Stone (1982b) and Nicholson et al (1982) also found that terfenadine 
(60mg) and astemizole (10 and 20mg) caused no impairments on psychomotor tasks 
such as dynamic visual acuity, but again triprolidine was found to impair 
performance. Nicholson and Stone (1983b) also examined the effects of mequitazine, 
an H-1 histamine receptor antagonist widely used for treating allergic states, on 
measures of visuomotor co-ordination, dynamic visual acuity and digit symbol 
substitution. Mequitazine, ingested at its therapeutic dose of 5mg, produced minimal 
effects, although there were a few impairments found with a 10mg dose some hours 
following ingestion. 
 
Betts et al (1984) in a controlled placebo study examined the effects of two 
antihistamine drugs (centrally active triprolidine and peripherally active terfenadine) 
on an actual driving task using female subjects. They found that only triprolidine 
significantly impaired performance. They therefore concluded that antihistamine-
using drivers should avoid those drugs which act centrally. However Bhatti (1989) 
found that terfenadine could impair driving-related psychomotor tasks in a dose-
related fashion in that only doses of 240mg caused impairment and not doses of 60mg 
or 120mg. This probably reflects the methodological differences between the two 
studies. 
 
de Gier et al (1986) tested twelve healthy male subjects on an actual driving test and 
psychomotor tests both before (day one) and after (day eleven) ingesting a placebo or 
astemizole (10mg three times per day for ten days). The driving test was 
approximately 60km long and lasted for approximately 90 minutes. Behavioural and 
 31
cognitive skills were rated on a scale from 'satisfactory' to 'insufficient'. Psychomotor 
tasks consisted of two attentional tasks, one highly demanding and the other not. They 
found that the groups did not significantly differ from each other on the day eleven 
driving tests. The laboratory tests revealed a slight improvement for the astemizole 
subjects, but this was not significant. The authors concluded that the subchronic use 
of astemizole in a dosage regimen of 10mg t.i.d. for seven days followed by 10mg 
daily for three days has no impairing effect on either car driving or psychomotor 
performance. 
 
OHanlon (1988) found that terfenadine (a non-sedating antihistamine) did not 
adversely effect vehicle weaving compared to placebo controls. Neither terfenadine or 
loratadine (also non-sedating) potentiated the adverse effects of alcohol on the driving 
measures. Similar results have been found for cetirizine: Gengo and Manning (1990) 
examined the central effects of cetirizine on psychomotor performance. They found 
that cetirizine (20mg) induced minimal changes in mental performance tests. 
 
Brookhuis et al (1993) investigated the effects of a relatively recent antihistamine, 
ebastine (given in doses of 10, 20 and 30mg), versus a control drug, triprolidine 
(10mg) on car driving performance in actual traffic using fifteen subjects. It was 
found that ebastine caused no changes in performance at any dosage either on day one 
or five of the test. In contrast, triprolidine (at 10mg) significantly increased the degree 
of weaving and the delay in following speed manoeuvres of a leading car compared to 
a placebo condition. Thus ebastine may be relatively safe for driving in doses up to 
30mg whilst triprolidine is likely to cause impairment. 
 
In a review of studies comparing the effects on actual driving of both 'sedating' 
antihistamines (triprolidine, diphenhydramine and clemastine) and 'non-sedating' 
antihistamines (terfenadine, loratadine, cetirizine, acrivastine, mizolastine and 
ebastine), O'Hanlon and Ramaekers (1995) found an array of results which suggest 
that some of the newer drugs both enhance and impair performance depending on 
dose. The effects of mizolastine (10mg) and cetirizine (10mg) were also examined by 
Patat et al (1995) in conjunction with alcohol (BAC 0.7g/l) in eighteen male 
volunteers. The alcohol was found to impair both actual and simulated driving in 
addition to tests of divided attention and adaptive tracking even after 5.5 hours. The 
other drugs did not impair driving ability or arousal but did impair the divided 
attention task after 6 hours. Additionally, after 7.5 hours, mizolastine impaired 
tracking speed performance and cetirizine impaired the same task from 1.30 to 7.50 
hours after initial administration. The authors also did not find an adverse interaction 
between the antihistamines and alcohol.  
 
 
2.6.2  Antihistamine Field Studies 
Starmer (1985) states that antihistamines are seldom suggested as causative factors in 
traffic crashes (although this may be due to lack of reportage). Certainly it is the case 
that there are very few field studies which indicate traces of the drug in accident 
victims.  Teo (1975) found that 25% of Australians tested positive for alcohol and of 
these, 5.4% reported that they had used antihistamines. In a Canadian study, Cimbura 
et al (1980) found antihistamines present in 2.1% of samples taken from Ontario 
drivers, although most of these were in combination with other drugs. 
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In a U.S. National Transportation Safety Board study (1990) of 168 fatal-to-the-driver 
heavy truck crashes, antihistamine was found to be in the body of only one driver. 
This lack of risk associated with antihistamine use was also reported by Ray et al 
(1992). They conducted a retrospective cohort study of Tennessee drivers aged 65 -84 
and calculated crash risk for four groups of psychoactive drugs including 
antihistamines. They found that increased risk was not associated with antihistamine 
use, but was with benzodiazepine use and cyclic antidepressants. These results could 
not be attributed to the confounding effects of alcohol use or driving frequency. 
 
 
2.6.3  Summary 
Peripherally active as opposed to centrally active antihistamines are less likely to 
cause impairing sedative effects (Nicholson and Stone, 1986). Some antihistamines 
which are slow to cross the blood brain barrier and thus produce tolerance without 
central effects, such as astemizole, and especially terfenadine, are likely to be of little 
detrimental effect on skilled performance. Meltzer (1990) concluded that the centrally 
active first generation agents commonly cause greater performance decrements as 
compared with the newer, non-sedating second generation antihistamines. Since 
antihistamines vary in the extent of their impairing effects it is important that doctors 
and users try to use the less toxic and impairing versions available. Therefore the use 
of antihistamines is not necessarily likely to result in impaired driving performance. 
This conclusion is supported by the very few epidemiological studies which find 
traces of antihistamines in blood samples from traffic accident victims. 
 
In a major report from the Institute for Drugs, Safety and Behaviour in the 
Netherlands (Wolschrijn et al, 1991), the mean impairment ratings shown in Table 3 
were given for most of the antihistamines referred to in this review (refer to reference 
for ratings on all other antihistamines). 
 
 
 
 
Table 3:  Impairment ratings for various antihistamines 
 
Drug Dosage Impairment Rating 
Astemizole 10.0/30.0 none 
Acrivastine 4.0/8.0 none 
Brompheniramine 4.0/8.0 insufficient evidence 
 12.0 moderate/not severe 
Cetirizine 10.0 none 
 20.0 minor 
Ebastine - no impairment 
Loratadine 10.0/20.0 none 
Mequitazine 5.0 none 
 10.0 moderate/not severe 
Terfenadine 60.0/120.0 none 
 240.0 minor 
Tripolidine 2.5/5.0 not severe/severe 
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2.7 Antidepressants 
Antidepressants are prescribed to selectively treat the symptoms of depression 
although they may also be used to treat some phobias and obsessive-compulsive 
disorders. They can be separated into tricyclic antidepressants, monoamine oxidase 
(MAO) inhibitors and the newer 'second-generation' antidepressants. Tricyclic 
antidepressants reach peak plasma levels in 30 - 60 minutes, although it can take 5 - 
10 days for plasma levels to stabilise and the main therapeutic effect may not be 
apparent for 1 - 4 weeks.  
 
Although there are great variations, they generally have long half-lives. MAO 
inhibitors reach peak blood levels in about 60 minutes and most of this is excreted 
within 24 hours. Despite this they have a long effect latency and therapeutic effects 
may be felt in about 10 days after regular doses. Doses are generally given in groups 
of 20 - 30mg twice a day. They can have very toxic side-effects however, including 
high blood pressure. They do not cause dependency or withdrawal effects. The newer 
second-generation antidepressants tend not to have the bad side-effects of the other 
drugs. Well known types are fluvoxamine, bupropion and fluoxetine (Prozac).  
 
The other main advantage of some of these drugs is the fact that they can begin to 
have therapeutic effects in a very short time. In general, antidepressants do not have a 
euphoric effect, therefore they are comparatively less likely to be abused. In addition, 
the majority of antidepressant users are middle aged women, who tend to have a low 
incidence of traffic accident involvement (Linnoila and Seppala, 1985). 
 
 
2.7.1  Antidepressant Experimental Studies 
Louwerens et al (1983) examined the acute effects of oxaprotiline (25mg t.i.d.), 
mianserin (10mg t.i.d.), amitriptyline (25mg t.i.d.), doxepin (25mg t.i.d.) and placebo 
on twenty healthy male subjects driving a car over a 100km circuit in normal traffic. 
They found that amitriptyline and mianserin impaired control on lateral position and 
speed. Doxepin also slightly impaired lateral position, but not speed control. 
Oxaprotiline caused no impairments. Thus the results suggest that amitriptyline and 
mianserin in particular impair driving performance. Further evidence for this was the 
fact that half the tests in the amitriptyline condition had to be terminated early due to 
an objective decision that to continue would be dangerous.  
 
In general the results compare favourably with earlier studies demonstrating 
impairments resulting from these tricyclics. In addition, Brookhuis et al (1986) 
confirmed these results for the same drugs, doses and conditions using EEG energy-
density spectra technology. They found that mianserin, amitriptyline and doxepin 
increased the amplitude of theta, or of both alpha and theta activity, whereas 
oxaprotiline  did not differ from placebo on this measure. However the authors admit 
that their use of healthy subjects tested on the first day of treatment might not be 
generalisable to real patients who are on a longer course of medication and 
consequently may not show impairments to such a degree. 
 
In two experiments, Gerhard and Hobi (1984) investigated the effects of certain 
antidepressants on the psychomotor abilities of actual depressive patients. In the first 
experiment, twenty patients were used who were on treatment regimes of either 
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maprotiline (150mg/day), lithium, dibenzepine (720mg/day) or two antidepressants in 
sequence, and compared with a control group of 32 healthy subjects. The tasks were a 
choice reaction test and a simple/divided attention test. Tests were administered on 
day one and again about two months later (day 2). They found that on the choice 
reaction time test the patients were significantly worse than controls on both days, but 
both patients and controls showed improvements across trials on each separate day, 
but no improvements were demonstrated  for either group between the two days.  
 
In the divided attention test, the differences between groups were barely significant, 
but there was a slight improvement between the two days in addition to an 
improvement across trials on both days, as before. In experiment two, seven male 
anxious-inhibited depressive inpatients being treated with amitriptyline were 
compared to seven healthy controls on the two tasks. Trial one was administered on 
day 1, trial 2 a week later, and trial 3 during maintenance dosage just before or after 
patients were discharged.  
 
Both controls and patients showed some improvement across trials on the divided 
attention test (although less remarkably for the patients), and in the choice reaction 
time test the subjects showed a significant deficit by trial three compared to controls. 
Overall however, taking both experiments into consideration, patients did demonstrate 
an improvement in performance, although they were worse than controls in all tests. 
The authors conclude that the deficits were slight and as such do not render patients 
'unfit' to drive. The degree of intra-individual variability amongst patients suggests 
that performance evaluation may be better using individuals as opposed to groups. 
 
Linnoila and Seppala (1985), in a review of the relevant literature, have found that 
studies which use healthy volunteers as subjects and have used only single doses have 
tended to show that the more sedative drugs produce more impairments. In addition, 
there is some evidence that in the acute phase, antidepressant dosage positively 
correlates with degree of impairment. Ranking drugs in order of impairing effects 
with the most impairing at the start, the authors found that the following list applies: 
Amitriptyline, Imipramine, Mianserin, Viloxazine, followed by least impairing drugs 
such as: Amoxapine, Desipramine, Doxepin, Nomifensine, Nortriptyline and 
Zimelidine. Where chronic doses are used in healthy subjects, some degree of 
tolerance to impairing effects becomes noticeable in the literature for most of these 
drugs, although the adverse effects of lithium can still be detected (Judd, 1979). 
 
Using real patients, Seppala and Linnoila (1980) have found that skills impaired by 
depression improve with continued use of antidepressants. In fact impairment of skills 
and sedative effects only lasted the first several days of treatment. This also includes 
the case of lithium (Linnoila and Seppala, 1985). 
 
Gerhard and Hobi (1986) note that impairments in psychomotor performance have 
been noted after single doses of nortriptyline, imipramine and viloxazine, although the 
less sedating drugs like viloxazine, like doxepine, provoke less impairment on some 
tasks, notably attention, vigilance and learning, than the more sedating drugs such as 
amitriptyline. 
 
Hindmarch, Harrison and Shillingford (1988) examined the effects of lofepramine 
(70mg), lofepramine (140mg), nomifensine (100mg), amitriptyline (50mg) and 
 35
placebo (all given at weekly intervals) on the psychomotor performance of ten healthy 
females. Amitriptyline, the positive control, resulted in the expected sedative effects. 
However lofepramine (70mg and 140mg) and nomifensine (100mg) were generally 
free from impairing effects. 
 
Ramaekers et al (1992) tested seventeen healthy subjects taking either moclobemide 
or mianserin over eight days on psychomotor tests. They found that whereas 
moclobemide was free of impairing effects, mianserin treatment caused impairments 
on most measures included tracking and driving-related abilities. The authors 
attributed the deficits primarily to the sedative effects of the mianserin. 
 
Herberg (1994) compared the effects of paroxetine (1 x 20mg/day) with doxepine (2 x 
50mg/day) and placebo, all administered over a three week period. After twenty days, 
ethanol was given (0.05% BAC). Sixty male and female subjects were given seven 
tests of visual orientation, forced concentration, simple reaction time, choice reaction 
time, reaction under stress, vigilance and motor co-ordination. It was found that 
paroxetine did not impair performance whereas doxepine resulted in impaired 
vigilance, motor co-ordination, concentration and simple reaction time. 
 
Robbe and O'Hanlon (1995) examined acute and subchronic effects of paroxetine (20 
and 40mg), amitriptyline (75mg/day - the active control) and placebo on actual 
driving and psychomotor performance in sixteen healthy subjects. Whilst 
amitriptyline had its expected sedative and impairing effects (although these were 
gone by day 8), paroxetine 20mg (therapeutic dose) was free of effects. Paroxetine 
(40mg) did not effect road tracking but did impair some other psychomotor tests 
persistently. They noted however that some dose-related side effects (e.g. nausea and 
delayed ejaculation) were reported by subjects during paroxetine treatment only. 
 
Vanlaar et al (1992) used two groups of twelve anxious outpatients receiving 
buspirone (5mg three times/day for first week, 20mg/day thereafter) or diazepam 
(5mg three times/day for duration). The driving test took place over a 100km stretch 
of road and subjects were required to maintain constant speed and steady lateral 
position. Whilst both drugs were equally effective in reducing anxiety symptoms, 
only diazepam impaired lateral position control in the first three weeks, but not in the 
forth week, and speed control was effected only in the first week. This suggests that 
impairments diminish as treatment duration lengthens. 
 
Vanlaar et al (1995) also examined the effects on actual driving performance of a 
relatively new antidepressant, nefazodone (100 and 200mg twice daily), the tricyclic 
imipramine (50mg twice daily) and placebo using twenty-four healthy subjects. They 
found that imipramine (the reference drug) impaired lateral driving position after a 
single dose but this effect diminished after repeated dosing. Minor impairments were 
also noted on psychomotor tests on day 1 and day 7. In contrast, single doses of 
nefazodone (both dosages) did not impair driving (in fact there was some 
enhancement) and had no or little effect on psychomotor performance. After repeated 
dosing, nefazodone (200mg only) produced slight impairment of lateral position 
control and dose-related impairments of cognitive and memory functions were found. 
Neither drug appeared to cause daytime sleepiness. 
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2.7.2  Antidepressant Field Studies 
Excluding the previously mentioned problems associated with epidemiological 
studies, it is the case that few studies show that antidepressants are detected in 
accident victims more than would be expected (Linnoila and Seppala, 1985).  Jick et 
al (1981), in an examination of 244 people hospitalised for traffic injuries, found that 
antidepressant use was similar in 'responsible' drivers and non-responsible drivers and 
passengers. It was only slightly higher in these groups than in the wider driving 
population. The authors suggest that  the results are due to the fact that people take the 
warnings on medicine bottles seriously. 
 
Alvarez et al (1992) analysed questionnaires from 675 Spanish drivers and found that 
3.4% were taking tranquillisers. Ray et al (1992) conducted a retrospective study of 
older drivers in Tennessee. They found that increased risk was confined to 
benzodiazepines (relative risk = 1.5) and cyclic antidepressants (relative risk = 2.2). 
For both these drugs, relative risk increased with dose, especially with high doses (2.4 
for greater-than-or-equal-to 20mg diazepam and 5.5 for 125mg amitriptyline). Further 
analysis also revealed that these results were not confounded by the presence of 
alcohol. Ray et al (1992) also showed that patients taking amitriptyline 125mg/day are 
six times more likely to be involved in a road traffic accident than patients taking 
other drugs. 
 
Currie et al (1995) analysed 229 blood samples from 'responsible-for-accident' and 
non-responsible drivers. They found that there was a higher incidence of tricyclic 
antidepressants and benzodiazepines amongst the responsible group compared with 
the non-responsible group. A similarly high prevalence was found by Deveaux et al 
(1996). They conducted a prospective study of 103 fatally injured drivers and 
pedestrians in France. Of the 29% of fatalities studied, half contained antidepressants. 
In contrast, Logan and Schwilke (1996), in an analysis of blood/urine samples from 
fatally injured drivers in Washington State found that whilst antidepressants were not 
greatly represented, there was a trend for them to be associated with a higher BAC, 
and they were more prevalent amongst the 45+ age group. 
 
 
2.7.3  Summary 
Although some studies indicate that antidepressants may impair performance in 
healthy subjects taking the drugs for a week or more, there still remains the fact that 
real patients' performance may actually improve as the result of the drugs relieving 
their depressive symptoms.  
 
Little is known about the effects of depression per se on driving abilities. 
Antidepressants can have both beneficial and detrimental effects on psychomotor 
performance. If possible, the newer, less sedating drugs should be used in preference 
to older drugs such as amitriptyline. Although these newer drugs are very effective in 
treating symptoms, they generally do not speed up recovery from the root depression 
which is the reason they were prescribed in the first place (it may be two weeks before 
an improvement is observable). Additionally, there is little research available on the 
newer, less sedative antidepressants in relation to their effects (other than sedation) on 
psychomotor performance. The side effects of the most popular antidepressant, 
fluoxetine, such as nausea and insomnia, can themselves effect driving (Sherwood, 
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1997). Where alcohol is combined with antidepressants, especially the more sedative 
ones, the worst impairments are generally seen in the initial phase of treatment and 
diminish after prolonged treatment. Still alcohol is a bigger problem, and the effects 
of severe, untreated depression on driving capacities may be worse than the effects of 
antidepressants. 
 
In a major report from the Institute for Drugs, Safety and Behaviour in the 
Netherlands (Wolschrijn et al, 1991), the mean impairment ratings shown in Table 4 
were given for most of the antidepressants referred to in this review (refer to reference 
for ratings on all other antidepressants). 
 
 
 
Table 4:  Impairment ratings for various antidepressants. 
 
Drug  Dosage Impairment Rating 
Amitriptyline 12.5/25.0/50.0/75.0 not severe/severe 
Bupropion 100.0 minor 
Butriptyline 25.0 minor 
Dibenzipine 80.0 none 
Doxepin 25.0/50.0 not severe/severe 
Fluoxetine 20.0/40.0/60.0 none/minor 
Imipramine 25.0 minor 
 50.0 not severe 
 75.0 severe 
Maprotiline 25.0 minor 
 75.0 moderate 
Mianserin 10.0/20.0 moderate/not severe 
Nortriptyline 10.0/50.0 minor 
 75.0 moderate/not severe 
Paroxetine 30.0 none 
Viloxazine 100.0 none 
   
 
 
 
2.8 Amphetamines 
Generally amphetamines may only be prescribed in certain countries for the treatment 
of narcolepsy, some eating disorders and attention deficit disorder in children. 
However it is a widely abused drug largely because of its euphoric effects. Effects 
may begin after 30 minutes and peak within 2 to 3 hours; a full dose has usually 
dissipated after 72 hours. Increased mental alertness and physical energy may result 
from 5-25mg doses. Higher doses can cause impairments of cognitive and 
psychomotor abilities. There is substantial evidence that tolerance develops especially 
to the euphoric effects of amphetamine. Psychosis may result from regular daily doses 
of 60 - 300mg. In a recent report on drugs other than alcohol and driving in the 
European Union (de Gier et al, 1995), it was stated that the incidence of known 
amphetamine abuse among drivers involved in traffic accidents was, in Denmark 
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(1993 survey): 3 cases (no total given); Spain (1992 survey): 1.0% of 289 cases; UK 
(1995 survey): 1.0%; and Italy (1994 survey): 1.0% of 200 cases. 
 
 
2.8.1  Amphetamine Experimental Studies 
Sometimes amphetamines are reported to result in psychomotor enhancement rather 
than impairment (e.g. Hurst, 1987). However such studies generally use low doses of 
stimulants. Earlier Laties and Weiss (1967) had confirmed that the main enhancing 
effects of amphetamine resulted from a restoration of baseline performance in 
subjects who were fatigued. They also noted enhancing effects of the drug on 
measures of motor co-ordination and control, monitoring, vigilance and physical 
endurance at low doses.  In 1962 Hurst had investigated the effects of amphetamine 
on risk-taking and found that increased risk resulted from doses of 10 -15mg. A 
further study (Hurst et al, 1967) revealed that the enhanced self-perception that is an 
effect of the drug also corresponded with greater risk-taking. Thus it would appear 
that the so-called positive effects of amphetamine could be the very reason for 
increased likelihood of impairment. 
 
Pickworth et al (1997) examined the effects on eight subjects of THC (1.3 and 3.9%), 
ethanol (0.3 and 1.0 g/kg), hydromorphone (1 and 3mg), pentobarbital (150 and 
450mg) and amphetamine (10 and 30mg - within the therapeutic range). Participants 
were then tested on several psychomotor tasks including reaction time, card-sorting 
and search tasks. They found that alcohol impaired all tasks, THC impaired only one 
measure out of fourteen, and amphetamine had little effect at all. This supports the 
idea that amphetamine produces little change in performance in unimpaired 
individuals. The authors admit however that the motor and cognitive demands of their 
tests may not accurately reflect those of real-life driving. 
 
There are only a few studies of ethanol-amphetamine interactions which have been 
reported, and the results are generally contradictory (Perez-Reyes et al, 1992). These 
authors used twelve subjects familiar with the recreational use of alcohol and 
amphetamines, and gave them either a placebo, 0.85g/kg ethanol, 0.09 or 0.18mg/kg 
dextroamphetamine. They were then tested on a test of reaction time, attention, 
memory, decision making and information processing. They found that ethanol 
impaired performance especially where accuracy and reaction time where concerned, 
and that this impairment was attenuated by dextroamphetamine in a dose-response 
fashion, although the dextroamphetamine per se did not improve performance on the 
tasks. 
 
 
2.8.2  Amphetamine Field Studies 
In epidemiological studies examining drugs and driving, amphetamine is rarely found 
(see for example Mason and McBay, 1984). This has sometimes led to the conclusion 
that it is of little significance where impaired driving is concerned. For example, 
Hurst (1987) concluded that therapeutic doses of amphetamine are no threat to traffic 
safety and may actually improve performance. In contrast, Smart (1969) had found a 
high rate of traffic accidents among amphetamine abusers. 
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Hurst (1976, 1987) in reviews of the field evidence, concluded that there was 
insufficient evidence to specifically implicate amphetamine use in traffic accidents, 
largely due to a lack of controlled studies. Lund et al (1988) found that only 2% of 
U.S. drivers voluntarily tested had taken methamphetamine, although the refusal rate 
was 12%. Crouch et al (1993) found a higher incidence (7%) in samples taken from 
fatally injured truck drivers. 
 
In a U.S. National Transportation Safety Board study (1990) of 164 fatal-to-the-driver 
heavy truck crashes, amphetamine was found to be in the bodies of 12 drivers (7.3%). 
A higher prevalence was found by Gjerde et al (1992). They examined the incidence 
of amphetamine in 380 suspected drugged drivers in Norway, where the drug is 
amongst the most commonly abused. As elsewhere, it is rarely used medically other 
than for the treatment of childhood hyperkinesia and narcolepsy where the dose given 
is 2.5-30mg daily. The authors found that 92% of the drivers had blood amphetamine 
levels greater than the therapeutic dose and 79% had other drugs present in addition to 
amphetamine. In 248 cases, clinical tests of impairment revealed that 84% of drivers 
were impaired (in the 49 cases were amphetamine was the only drug found, 78% were 
impaired). The authors concluded that amphetamine abuse may therefore lead to 
irregular or dangerous driving resulting in traffic accidents. 
 
Drummer (1995) found that out of 1052 samples from fatally injured drivers, 
amphetamines (and related stimulants) were found in 35 cases. However, because of 
the very high incidence of alcohol involved in all cases, the author concluded that 
drugs were only responsible in a small proportion of cases compared to alcohol. 
Kriger et al (1995), in a German Roadside Survey from 1992 to 1994 of 2234 drivers, 
found that amphetamines were present in 0.6% of cases. This is a useful result since 
the results were adjusted to reflect a representative driving population. As a 
cautionary note, however, Pidetcha et al (1995) have found that quite different 
numbers of positive samples can be detected depending on the exact type of 
immunoassay screeening technique which is used. 
 
In a Norwegian study, Christopherson et al (1995/96) found that amphetamines were 
present in 4.1% of the samples tested (n = 394). However alcohol was found in 
62.9%, benzodiazepines in 13.7%, cannabis in 7.5% and opiates in 4.3%. Overall the 
authors conclude that drivers taking any of these drugs, including amphetamine run a 
considerable risk of being involved in an accident. 
 
Rohrich et al (1995) noted that there had been a significant increase in amphetamine-
positive cases amongst drivers in Greater Frankfurt  between 1987 (0.49%) and 1993 
(9.40%). They further noted that in 80% of cases amphetamine had been consumed in 
combination with cannabis, with additional use of tranquillisers and occasionally 
cocaine. Since only impaired drivers had been screened in this sample, the number of 
undetected cases must remain unknown.   
 
Logan (1996) examined the records of 28 drivers arrested or killed in accidents and 
who had tested positive for methamphetamine. Most of the arrests resulted from 
accidents in which the driver was responsible. Although methamphetamine-alcohol 
combinations were uncommon, use of cannabis was traced in approximately a third of 
the cases. The main driving impairments were: drifting out of lanes, erratic driving, 
weaving, speeding, drifting off the road and high speed collisions. Logan suggests 
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that some of the impairments may have been caused by methamphetamine withdrawal 
which can cause impaired judgement and increased risk-taking. He concludes that 
usage of amphetamines at any dosage is likely to render the user unsafe on the roads. 
In an additional study, Logan and Schwilke (1996) found that amphetamines 
accounted for 2% of samples taken from fatally injured drivers in Washington State. 
 
Pelisser et al (1996) compared drug use (including amphetamines) in young adults 
involved in road accidents and a control group. Interestingly they found no significant 
differences between the two groups. Augsberger and Rivier (1997) found only 4% of 
samples from 641 suspected drivers in Canton de Vaud contained amphetamine, and 
most samples were combined with alcohol. A small amphetamine prevalence was also 
found by Marquet et al (1998). They compared drug levels in urine samples of injured 
drivers (n = 296) in France with a comparable group of non-accident victims (n = 
278). Amphetamines were found in 1.4% of drivers and 2.5% of controls. They 
concluded that, unlike suggestions from other studies in other countries, amphetamine 
use did not appear to be a significant problem in the context of driving safety. 
 
Recently Logan et al (1998) investigated 146 accident reports in which 
methamphetamine had been found in the drivers. Of these cases, 52 were drug-caused 
and in 92 the drug was not directly responsible for the accident. In these 92, the 
median concentration level was 0.42mg/l (range 0.05 - 9.30mg/l) and 90% of these 
had concentrations under 2.20mg/l. The highest concentrations were in the 
accidental/undetermined drug-caused deaths. In the methamphetamine related traffic 
deaths, blood concentrations  ranged from 0.05 - 2.60mg/l (median 0.35mg/l). This 
means that most of the methamphetamine deaths occurred with blood concentrations 
greater than 0.5mg/l, but could occur with levels as low as 0.05mg/l, although other 
drugs or disease were contributory factors. 
 
 
2.8.3  Summary 
Sherwood (1997) concludes that at lower doses amphetamines have few effects on 
cognitive functioning, but at higher doses risk-taking increases and responses become 
inappropriate. Therefore whilst there may be subjective positive effects associated 
with amphetamine use, these same effects especially at higher doses, could result in 
personality changes leading to an increased likelihood of impaired driving.  
 
Only a few studies have directly examined alcohol-amphetamine interactions and the 
results are often contradictory. In general, high doses of amphetamine are likely to 
increase the impairing effects of alcohol. In a major report from the Institute for 
Drugs, Safety and Behaviour in the Netherlands (Wolschrijn et al, 1991), three 
experts rated amphetamine and dextroamphetamine (5 and 10mg) as likely to cause 
'moderate/no severe' impairment. 
 
 
 
2.9 Ecstasy and Other Synthetic Drugs 
Where these drugs are concerned there is little experimental and field evidence 
available regarding their effects on the driving act. Therefore studies must be 
examined which have investigated prevalence in various other populations or which 
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have looked at the effects of the drugs on cognition, and extrapolate from these to the 
likely effects on driving. This section will correspondingly not have separate sections 
on experimental and field studies. 
 
 
2.9.1 Ecstasy 
Ecstasy has been the most prominent designer drug of the eighties and nineties largely 
due to its popularity on the dance and 'rave' scene. Its technical name is MDMA (3,4-
methylenedioxymethamphetamine), one of the MDA family of hallucinogenic 
amphetamines which also include MMDA, MBDB and MEDA. Most MDMA use is 
oral with initial doses ranging from 20 - 180mg and supplementary doses of about 
40mg. Effects begin after 20 - 60 minutes. Pills may contain toxic ingredients such as 
atropine, although more commonly flunitrazepam, caffeine, ephedrine and quinine. 
The best known effects are subjective feelings of positive mood/self-image and 
intimacy with others. Such effects may last for a week. Sometimes hallucinogenic 
experiences are encountered similar to LSD. Side-effects may include tension, tremor, 
nausea, insomnia and reduced appetite. 'Flashbacks' are also possible.  
 
At very high doses the drug is potentially lethal and indeed there have been several 
high-profile deaths reported in the media, although whether these can be attributed to 
the direct action of the drug itself, to dehydration, or even to excessive fluid intake, is 
still a matter of debate (UK Parliamentary Office of Science and Technology, 1996). 
Tolerance develops to MDMA, but no physical dependence. It was originally 
developed as an appetite suppressant and has also been put to, largely unofficial, 
psychotherapeutic use. The popularity of the drug has resulted in the establishment of 
many underground laboratories manufacturing other designer synthetic drugs, most of 
which are substituted phenethylamines and often based on 'recipes' from 'PIHKAL' 
('Phenethylamines I Have Known And Loved') by Dr. Alexander and Ann Shulgin, 
which is widely available through the Internet. (See section on new synthetic drugs). 
 
To date, no studies have directly examined MDMA effects on driving performance, 
although there are a few which have looked at cognitive and perceptual effects, which 
may have relevance to driving. For example,  DuPont and Verebey (1993) examined 
the effects of MDE or placebo on fourteen normal subjects. They found that subjects 
who had taken MDE displayed a general stimulation with increased psychomotor 
drive. One subject developed a toxic psychosis, one displayed dysphoric reaction and 
one suffered from anxious episodes for several days following the test. 
 
Moeller and Hartung (1997) cite a controlled clinical study by Helmlin et al (1996) of 
two subjects taking MDMA. The applied dose was 1.5mg/kg body weight, which is 
notable because this is also the approximate dose ingested by a consumer at a 'rave' 
disco. A delay in breakdown of MDMA can occur and this is very relevant where 
participation in road traffic is concerned. It is possible thus that an acute influencing 
effect is still evident many hours after the original ingestion. 
 
Curran and Travill (1997) investigated the acute and residual effects of MDMA on 
twelve MDMA users and twelve subjects who reported that they had only consumed 
alcohol. Measures were taken of participants' mood and cognitive function. On day 1, 
MDMA users reported an elevated mood, but this had significantly decreased to the 
extent of clinical depression in some users by day 5. The alcohol group showed less 
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pronounced changes with the lowest mood rating occurring on day 2. The MDMA 
group also evidenced significant impairments on an attentional/working memory task 
compared with alcohol users. These results have obvious ramifications for driving 
behaviour. 
 
Parrott et al (1998) administered a battery of psychomotor tests to three groups of 
subjects: ten regular MDMA users, ten novice MDMA users who had tried ecstasy 
one to nine times, and ten control subjects who had no experience of the drug. All 
tests were given on a drug-free day. Results indicated that the three groups did not 
differ on measures of simple reaction time, choice reaction time and number 
vigilance, but that both MDMA groups were impaired relative to controls on 
immediate word recall and delayed word recall. These findings are consistent with 
other work indicating memory decrements in ecstasy users. 
 
Creighton et al (1991) found 3 cases of flashbacks and 1 case of recurrent psychosis 
following MDMA consumption. In a case more specifically related to driving, Hooft 
and Can de Voorde (1994) cited the single case of a fatal car accident involving a 26 
year old man who tested positive for MDMA (0.63mg/l), although alcohol was also 
involved as well as amphetamines. 
 
Moeller and Hartung (1997) in studies carried out in 1995 and 1996 were able to 
prove the presence of ecstasy and related substances in impaired drivers in 30 cases. 
The presence of MDMA was demonstrated in 18 cases and MDEA in 17 cases (the 
latter alone in 5 cases). In all of the other cases there was a combination of these 
substances, sometimes with amphetamine. MDA was found in 23 cases. They noted 
that THC was also found in 25 of the 30 drivers with ecstasy in their blood. 
 
Giroud et al (1997) examined the extent of use of MDMA in Switzerland where 
ecstasy and other phenylethylamines are used extensively at 'raves' and where there 
has been an increasing number of MDMA-related deaths. Qualitative analysis of 
street samples indicated that only some of them contained MDMA or related 
phenylethylamines (MDA, MDEA, MBDB and 2c-B). Most of them were mixed with 
caffeine and an excipient. Also detected were amphetamine cut with caffeine, 
stimulants and LSD. Quantitative analysis revealed  large fluctuations in the amount 
of active substance(s) per tablet. Forensic analysis of blood samples from people 
suspected of driving whilst under the influence of psychoactive drugs determined that 
there were significant levels of MDMA, MDEA and MDA. However the variable 
composition of tablets indicates that unpredictable types and amounts of drugs may be 
taken by MDMA abusers. They conclude that there is major concern that traffic 
accidents may be caused by MDMA users, especially when combined with other drug 
types. 
 
In an interim report published by the Department of the Environment in the UK 
(1998), it was found that a sample of 619 road user fatalities contained virtually no 
amphetamine users including ecstasy users. In contrast, the drug most frequently 
detected was cannabis, but the usual problems apply when trying to estimate the true 
role of this drug in accident causation. The authors conclude that alcohol is still a 
much larger problem than that represented by drugs. 
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Windhaber et al (1998) describe the case of a young female who developed panic 
disorder after multiple ingestion of MDMA. This was successfully treated with 
Paroxetine (a serotonin re-uptake inhibitor) after 3 months of treatment. It is such 
unpredictable side-effects which make ecstasy a potential danger amongst drivers.  
Interestingly, a recent report from the Ministry of the Interior, Paris (1997) estimated 
that ecstasy-related traffic offences accounted for 3% of drug-related traffic offences 
in France. 
 
 
2.9.2  GHB 
Gamma-hydroxybutyric acid (GHB) is a naturally occurring transmitter in the 
mammalian brain, related to sleep regulation and possibly to energy balance. GHB 
was first introduced in clinical anaesthetic practice more than 35 years ago. Although 
GHB can induce a reliable state of sedation and anaesthesia without depressing either 
respiratory or cardio-circulatory parameters or liver and kidney function, the drug was 
nearly displaced from clinical practice because of its prolonged duration of action 
(Kleinschmidt and Mertzlufft, 1995).  
 
In addition to its use as an anaesthetic, GHB may be useful in the treatment of alcohol 
and opiate withdrawal syndrome, has been investigated as a tool for inducing absence 
seizures, and for treatment of narcolepsy. Since 1990 GHB has been abused in the 
United States for euphoric, sedative and anabolic effects. Coma and seizures have 
been reported following its abuse. Adverse effects of GHB may include prolonged 
abuse, seizure activity and a withdrawal syndrome (Galloway et al, 1997). This 
withdrawal syndrome includes insomnia, anxiety and tremor; symptoms resolve in 3-
12 days. GHB is not detected with common drug screens. The compound is easily 
available since it can be produced simply in the home. 
 
GHB has been illicitly marketed by body builders as a growth hormone releaser. 
Steele and Watson (1995) report two cases from Kansas City where the patients 
presented in, or developed profound coma. They conclude that physicians should 
suspect GHB poisoning in patients who present with unexplained seizures and/or 
coma, particularly if they are body builders, health food fanatics or dieters. 
 
Li et al (1998) described seven patients presenting with combination substance abuse 
involving GHB. All patients presented with acute delirium and transient but severe 
respiratory depression. With supportive care, including intubation and mechanical 
ventilation in four cases, normal mentation and respiratory function returned within 2 
to 6 hours. None of these patients had documented seizures, and none of the four 
patients who received naloxone intervention had a reversal response. This clinical 
observation supports previous experimental work in GHB-intoxicated human subjects 
demonstrating neither epileptiform changes on electroencephalography nor reversal 
with naloxone. In one patient they observed a peculiar state of violent aggression 
despite near or total apnea. 
 
Hernandez et al (1998) have described what may be the first psychiatric 
hospitalisation due to GHB-induced delirium reported in the medical literature. A 
patient presented with a chief complaint of feeling suicidal and a 1-year history of 
GHB use.  Chin et al (1998) assembled a retrospective series of all cases of GHB 
ingestion seen in an urban public-hospital emergency department and entered in a 
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computerised database from 1993 to 1996. They concluded that patients who 
overdosed on GHB presented with a markedly decreased level of consciousness. 
Patients typically regain consciousness spontaneously within 5 hours of the ingestion. 
Similar findings have been reported by Williams et al (1998). They found that 
profound unconsciousness occurred in all cases (six) and despite full (and often rapid) 
recovery all patients required medical intervention. Adverse effects occurred both 
when GHB was used alone or in combination with other illicit drugs and alcohol. 
 
In a case more specifically related to driving, Stephens and Baselt (1994) reported the 
case of a driver who was found asleep behind the steering wheel of his car, and the 
vehicle was at rest in a traffic lane with the engine running. His manifestations 
included horizontal and vertical gaze nystagmus, muscle flaccidity, and severe ataxia. 
He admitted ingesting a white powder, which he identified as an amino acid, about 1 
hour prior to discovery by police. A urine specimen collected approximately 1 hour 
after the traffic stop contained 1975 mg/L of GHB. They tentatively concluded that 
GHB may cause impairment of the psychomotor skills required for safe operation of a 
motor vehicle. 
 
 
2.9.3  Ketamine 
The intravenous anaesthetic ketamine is widely used in sub-anaesthetic doses as a 
potent analgesic in emergency and disaster medicine. Among the different sites of 
action, N-methyl-D-aspartate (NMDA)-receptor antagonism is considered to be the 
most important neuropharmacological mechanism of ketamine. Following intravenous 
administration, a rapid onset of action is seen within 1 minute, lasting for about 10 
minutes. The most important adverse effects are hallucinations and excessive 
increases in blood pressure and heart rate.  
 
These reactions can be attenuated or avoided by combining of ketamine with sedative 
or hypnotic drugs like midazolam and/or propofol (Adams and Werner, 1997). 
Former studies suggested that ketamine is a proconvulsive agent; however, recent 
studies have demonstrated anticonvulsive and even neuroprotective properties (Detsch 
and Kochs, 1997). Subanaesthetic doses of ketamine can produce psychedelic effects 
in healthy volunteers (Bowdle et al, 1998). A standard recreational dose of ketamine 
is typically 1/8 g, usually taken intranasally, with effects lasting for approximately 
one hour. It is one of the drugs consumed regularly amongst members of the new 
dance culture. 
 
Hersack (1994) in a review of the literature, found that after 25 years of clinical 
experience with ketamine, fewer than 10 cases documented the occurrence of delayed 
psychological effects potentially attributable to that drug. In most cases, the delayed 
effects were temporary, resolving within 3 weeks. Further, there were no long-term 
psychological effects clearly attributable to ketamine. Hersak notes that several 
controlled studies investigating the risk of long-term psychological effects due to 
ketamine fail to document that the risk of permanent psychological changes from 
ketamine is any greater than that from any other anaesthetic. The author concludes 
that there is no evidence in the literature that ketamine presents a higher risk 
compared to other anaesthetics for causing long-term psychological effects that result 
in a patient not being able to return to his or her occupation. 
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In contrast Krystal et al (1994) tested 19 healthy subjects following ingestion of 
ketamine hydrochloride (0.1 mg/kg), or ketamine hydrochloride (0.5 mg/kg). 
Ketamine (1) produced behaviours similar to the positive and negative symptoms of 
schizophrenia; (2) elicited alterations in perception; (3) impaired performance on tests 
of vigilance, verbal fluency, and the Wisconsin Card Sorting Test (a test of frontal 
lobe function); (4) evoked symptoms similar to dissociative states; and (5) 
preferentially disrupted delayed word recall, sparing immediate recall and 
postdistraction recall. These data indicate that NMDA antagonists produce a broad 
range of symptoms, behaviours, and cognitive deficits that resemble aspects of 
endogenous psychoses, particularly schizophrenia and dissociative states. 
 
Pfenninger et al (1994) evaluated ketamine's analgesic and psychotropic effects in 
subanaesthetic doses given to 16 healthy volunteers. Subjects received ketamine 
racemate (1 mg/kg) and S(+)-ketamine (0.5 mg/kg) i.m. with 1-week intervals 
between injections. Analgesia (electric pain stimulation of the median nerve), long-
term memory, anterograde amnesia (recognition of simple pictures), motor co-
ordination (Trieger test), immediate recall (short test of general intelligence) and 
concentration capacity (test: recognition of a preselected symbol among several 
symbols) were measured over a 60-minute period and mean arterial pressure, heart 
rate, and ketamine plasma levels in venous blood samples were determined. Within 15 
minutes, both agents induced a measurable degree of analgesia. Ketamine racemate 
did not exert measurable effects on long-term memory, whereas anterograde amnesia 
was observed in 46% and 54% of the study subjects after 15 and 30 minutes, 
respectively. However, after S(+)-ketamine, only 8% of the volunteers demonstrated 
anterograde amnesia. Immediate recall also declined in both groups whereas 
concentration capacity worsened after ketamine racemate and significantly less, after 
S(+)-ketamine. 
 
Malhotra et al (1997) found that, following ketamine ingestion, schizophrenics 
experienced a brief-ketamine-induced exacerbation of positive and negative 
symptoms with further decrements in recall and recognition memory. They also 
displayed greater ketamine-induced impairments in free recall than normals. 
Qualitative differences included auditory hallucinations and paranoia in patients but 
not in normals. These data indicate that ketamine is associated with exacerbation of 
core psychotic and cognitive symptoms in schizophrenia. Moreover, ketamine may 
differentially affect cognition in schizophrenics in comparison to normal controls. 
 
Adler et al (1998) administered ketamine (0.12 mg/kg bolus and 0.65 mg/kg/hour) to 
10 healthy volunteers to characterise the formal thought disorder and specific memory 
dysfunction associated with ketamine. Thought disorder was evaluated with the Scale 
for the Assessment of Thought, Language and Communication. Cognitive testing 
involved working and semantic memory tasks. They found that ketamine produced a 
formal thought disorder, as well as impairments in working and semantic memory. 
The degree of ketamine-induced thought disorder significantly correlated with 
ketamine-induced decreases in working memory and did not correlate with ketamine-
induced impairments in semantic memory.  
 
Finally, in a further study by Krystal et al (1998) in normal volunteers, it was 
demonstrated that ketamine produced behaviours similar to the positive and negative 
symptoms of schizophrenia as assessed by the Brief Psychiatric Rating Scale (BPRS). 
 46
It also evoked perceptual alterations as measured by the Clinician-Administered 
Dissociative States Scale (CADSS) and impaired performance on the Wisconsin Card 
Sorting Test and other tests sensitive to frontal cortical impairment.  
 
 
2.9.4  PCP 
Phencyclidine (PCP) or "angel dust" is a dissociative anaesthetic agent with notoriety 
as an abuse substance. A derivative of the anaesthetic ketamine, PCP is the 
predominant member of the arylhexylamine class of 'designer drugs' (Buchanan and 
Brown, 1988). States of florid psychosis lasting for days can follow a brief encounter 
with PCP (Isaacs et al, 1986).  
 
Pradhan (1984) summarised the observations of many investigators which showed 
that the acute effects of PCP following several routes of administration were shown to 
be dose-related. High doses of PCP produce disturbing manifestations including 
psychosis, numbness, light-headedness, vertigo, ataxia, and nystagmus due to acute 
intoxication. Furthermore, some subjects became irritable, argumentative or negative 
under the conditions of social stress and demanding tasks. In addition to a variety of 
central actions, PCP has also been shown to affect cardiovascular function, heat 
storage, and exercise performance. It can also induce, although rarely, psychotic 
episodes in psychotic and pre-psychotic personalities.  
 
Tolerance, but not physical dependence, develops to the effects of PCP. Psychological 
dependence as indicated by craving for the drug has however been reported. The 
elicitation of violent of psychotic behaviour by phencyclidine is well documented. 
There are indications, however, that behavioural responses to PCP may differ among 
PCP users as a function of background or personality characteristics, (McCardle and 
Fishbein, 1989). PCP is generally less abused in Europe in comparison to the U.S.A. 
 
Graeven et al (1981) analysed a sample of 200 phencyclidine users from an area with 
a 10-year history of extensive PCP use. Three types of users were studied: heavy 
chronic, light chronic, and recreational users. Results showed that heavy chronic users 
were more likely than recreational users to feel energised by PCP, and to experience 
negative ideations (thoughts about suicide and death). When age was controlled for, 
heavy chronic users were also more likely to experience violent effects. Analysis of 
moods over time showed some similar patterns between heavy chronic and 
recreational users, as well as some striking differences. Overall, heavy chronic users 
reported greater mood elevations while high on PCP, and a more dramatic drop in 
mood after the high wore off, than recreational users. 
 
Gorelick and Wilkins (1989) screened 155 consecutive admissions to a voluntary, 4-6 
week substance abuse inpatient rehabilitation programme. They found a 13% 
prevalence of PCP abuse and a 23% prevalence of nonabusive PCP use, as defined by 
DSM-III criteria. A majority of both abusers (80%) and users (97%) also abused other 
drugs, including alcohol (57%), opiates (29%), marijuana (29%), and stimulants 
(18%). Six patients still had PCP detected after 4 weeks of hospitalisation, without 
evidence of PCP reuse. These findings suggest that PCP abuse and use are common 
among unselected patients seeking substance abuse inpatient treatment. 
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Poklis et al (1990) conducted a survey of 104 deaths involving PCP occurring from 
1981 through 1986 in Missouri. Four males died from fatal PCP intoxication. PCP 
was detected in an additional 100 deaths. In 50% of deaths where PCP was detected, 
other drugs were co-administered: ethanol (35%) and cocaine (20%) being the most 
common mixtures. A dramatic continuous increase in PCP abuse from 1984 through 
1986 was demonstrated by drug abuse indicator data: treatment admissions, 
emergency room episodes, police exhibits, and driving under the influence of PCP 
arrests. Increased abuse of PCP in Missouri has been associated with increased 
medical emergencies and violence against persons. 
 
Cosgrove and Newell (1991) administered a battery of 12 neuropsychological tests on 
two occasions to 15 chronic PCP users who reduced or eliminated use of PCP over a 
4-week period. A comparison sample of 15 non-PCP drug users who did not differ in 
age, sex, education, and ethnic composition also were tested at the two time periods. 
Impairment, initially higher for PCP users, decreased significantly after reduction in 
use of PCP. A nonsignificant increase in impairment was found for non-PCP drug 
users. Analysis of each variable revealed that substantial improvement occurred on 
the acquisition, recall, and delayed recall scores of the Randt Memory Test. 
Improvement also was noted for some individuals on Trails B and Digit Symbol tests. 
 
Previous studies indicate that PCP users have different characteristics from other drug 
users and that female PCP use is more common than use among males. Furthermore, 
there is evidence that those who respond to PCP with violence may differ from those 
who do not. Fishbein (1996) found that female PCP using subjects reported more 
dysphoria and aggressiveness when not using PCP, while male subjects were more 
likely to report aggressive behaviour and dysphoria under the influence. 
 
Where screening is concerned, Nakahara et al (1997) have reported the simultaneous 
detection in hair of phencyclidine (PCP) and its two major metabolites, 1-(1-
phenylcyclohexyl)-4-hydroxypiperidine (PCHP) and trans-1-(1-phenyl-4-
hydroxycyclohexyl)-4'-hydroxypiperidine (t-PCPdiol). However the recent consensus 
is that hair analysis in general is a poor screening method (see following section on 
drug testing). 
 
 
2.9.5  Fentanyl 
Fentanyl, like methadone, is sometimes used as a heroin substitute but is primarily 
used as an anaesthetic during major surgery. At therapeutic doses the drug is safe and 
can produce a euphoric effect, but at high doses respiratory arrest can occur. Like 
many of the newer synthetic drugs, there exist many fentanyl analogues as a result of 
diffuse underground laboratory activity. 
 
Ghoneim et al (1975) gave 10 healthy male subjects diazepam (10 or 20 mg), fentanyl 
(0.1 or 0.2 mg) or a placebo intravenously at weekly intervals. They were tested on a 
battery of psychological and electroencephalographic tests at 0.5, 2, 6, and 8 hours 
following injection. Fentanyl had little effect on memory while diazepam reduced the 
ability to learn without increasing forgetting of material already acquired. By the 
second hour post injection, only the low dose of fentanyl had no residual effect. 
Recovery was complete by the sixth hour for all treatments according to the 
psychological tests except for the lagging effect of high doses of diazepam on 
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memory. The electroencephalographic effects of diazepam persisted beyond the end 
of the testing sessions while those of the high dose of fentanyl recovered by the eighth 
hour.  
 
Thus in the dosages tested, diazepam had more intense and prolonged effects than 
fentanyl. Interestingly, however, the opposite dichotomy was found in a driving study 
conducted by Stevenson et al (1986). They compared the effect of fentanyl (100 
micrograms), diazepam (7.5 mg), and placebo on the driving ability of young 
volunteers as measured by the tachometer. Speed and accuracy were impaired at 30 
and 120 minutes by both drugs, and by fentanyl more than diazepam. 
 
Sold et al (1983) tested seven subjects on a quasi continuous word recognition task 
i.e. after a preload list of 150 words played on a tape they had to indicate if the 
following words (grouped into 10 blocks of 100 words each) were new ones or had 
occurred already. Interposed were measurements of reaction time to a visual stimulus, 
and of concentration and short-time memory. During the experiment, unknown to the 
test person, diazepam 10 mg/70 kg, flunitrazepam 1 mg/70 kg, fentanyl 0.15 mg/70 
kg or placebo were infused over 3 minutes. The results clearly indicated that only the 
benzodiazepines specifically impaired memory function, the effect of flunitrazepam 
being more pronounced and longer in duration. 
 
Zacny et al (1992) examined in thirteen healthy volunteers the subjective and 
psychomotor-impairing effects of intravenous fentanyl (0-100 micrograms/70 kg). A 
randomised, placebo-controlled, crossover design was used in which subjects were 
injected with 0, 25 (N = 6), 50 and 100 micrograms/70 kg fentanyl in a double-blind 
fashion. Subjects completed several questionnaires commonly used in abuse liability 
testing studies before drug injection and at periodic intervals for up to 3 hours after 
drug injection. Subjects also completed several psychomotor tests at these times. 
Some aspects of psychomotor functioning (e.g., eye-hand co-ordination) were 
impaired by fentanyl. Fentanyl produced dose-related increases in ratings of "high" 
and "sedated," but also tended to produce dysphoria and somatic symptomatology.  
 
Veselis et al (1994) administered fentanyl or placebo to nine healthy volunteers by 
continuous i.v. infusion, targeting plasma concentrations of 1, 1.5, and 2.5 ng/mL in 
succession. A battery of memory and psychomotor tasks was administered at each 
plasma concentration of fentanyl, and at two points in the recovery phase while drug 
levels were decreasing. At increasing plasma concentrations of fentanyl, they found 
the following effects on memory (in comparison with placebo): a progressive decline 
in verbal learning; decreased delayed recognition of words presented at different test 
times; and decreased spontaneous recall of pictures shown during infusion. Fentanyl 
at concentrations above 2.5 ng/mL caused a performance decrement of 15%-30% 
relative to baseline on all the psychomotor tests administered. Plasma concentrations 
less than 2.25 ng/mL had negligible effects on performance with the exception of the 
critical flicker fusion frequency, which decreased by 5 Hz at plasma concentrations 
between 1.5 and 2.25 ng/mL. Visual analogue scale (VAS) measures of mental and 
physical sedation were significantly affected by fentanyl, but euphoria was not 
demonstrable. All subjects receiving fentanyl experienced severe nausea and four of 
six had one or more episodes of emesis. 
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Thapar et al (1995) compared impairment caused by different sedative/analgesic 
combinations commonly used in ambulatory settings to that of alcohol at BACs 
higher than or equal to 0.10%. Impairment was measured via subjective (mood) and 
objective (psychomotor performance) assays. Twelve healthy volunteers were 
exposed to five drug conditions across 5 weeks. Each of the following drug conditions 
were adjusted for body weight (per 70 kg): fentanyl 50 micrograms and propofol 35 
mg (FP), fentanyl 50 micrograms and midazolam 2 mg (FM), fentanyl 50 
micrograms, midazolam 2 mg, and propofol 35 mg (FMP), alcohol 56 g (orally 
administered), and placebo. With the exception of alcohol, the other drugs were 
administered via the intravenous route. Psychomotor impairment caused by alcohol at 
15 minutes postingestion was used as a benchmark with which impairment caused by 
other sedative/analgesic combinations was compared. All the study drug combinations 
produced impairment (i.e., impairment greater than that seen with placebo), similar to 
that observed with alcohol at a BAC of 0.11%. 
 
 
2.9.6  Ephedrine and Phentermine 
There has been little study of the abuse liability of ephedrine, a naturally occurring 
drug used in medicine for thousands of years and currently sold as a "legal" stimulant 
(Chait, 1994). Most studies show that, as a stimulant, ephedrine does not improve 
performance. More recently, ephedrine has been purported to be effective as a fat 
burner and used by athletes to maintain or improve muscle mass. Although research 
on individuals with obesity supports the use of ephedrine for fat loss, no studies have 
been done on athletes (Clarkson and Thompson, 1997). Clinically it is also used for 
treatment of asthma, allergic disorders and narcolepsy. Phentermine is also used to 
treat obesity and may have useful effects in the treatment of drug abuse. Phentermine 
is an anorexigenic drug with catecholaminergic action and may be used in moderate 
or severe obesity (BMI > 30 kg/m2) after a complete clinical assessment and in the 
context of an integral medical treatment. 
 
In a randomised, placebo-controlled, double blind study by Toubro et al (1993), 180 
obese patients were treated by diet (4.2 MJ/day) and either an ephedrine/caffeine 
combination (20mg/200mg), ephedrine (20mg), caffeine (200mg) or placebo 3 times a 
day for 24 weeks. They conclude that the ephedrine/caffeine combination is effective 
in improving and maintaining weight and that the side effects are minor and transient 
and no withdrawal symptoms have been found. 
 
Chait (1994) measured the reinforcing and subjective effects of ephedrine in a group 
of 27 adults with no history of drug dependence. A discrete-trial choice procedure was 
used to assess the reinforcing effects of a single oral dose of ephedrine selected to 
produce a moderate subjective response in each subject (range: 37.5-75 mg). Of the 
27 subjects, 5 chose ephedrine on either 2 or 3 out of a possible 3 occasions; overall, 
ephedrine was chosen on 17% of occasions. In the group as a whole, ephedrine had no 
effect on ratings of drug liking, but did increase ratings of "high" and scores on the 
MBG ("euphoria") scale of the Addiction Research Centre Inventory. Ephedrine also 
increased scores on a number of mood scales reflecting CNS stimulation and anxiety. 
Ephedrine choice was positively associated with current use of marijuana and lower 
levels of baseline anxiety and hunger, as well as with lower scores on two scales 
measuring dimensions of the personality trait of harm avoidance. Males and females 
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differed in their response to ephedrine; males chose ephedrine more frequently than 
females and showed a more positive mood response to the drug. 
 
Kuitunen et al (1984) tested the physical and mental effects of a single oral dose of 
ephedrine (ephedrine HCl 30 or 40 mg), fenfluramine (fenfluramine HCl 15 or 20 
mg), phentermine (7.5 or 11.25 mg) and prolintane (prolintane HCl 10 or 20 mg). 
Each group consisted of 16-43 healthy volunteer medical students. Memory, learning 
and concentration ability were evaluated with sign recording and digit span tests. In 
the digit span test no changes were obtained. In the sign recording test (for 3 min), 
phentermine increased significantly the recording score at both 1.5 hour and 2.5 hr 
and prolintane at 2.5 hour after drug administration. The results suggest that in the 
doses given, which are commonly used in medical practice, ephedrine has the most 
pronounced cardiovascular effects, while phentermine and prolintane seem to be most 
active in the performance of some mental tasks. 
 
Brauer et al (1996) tested the effects on 14 healthy subjects of d-amphetamine (10 and 
20 mg), phentermine (30 mg), fenfluramine (40 and 80 mg), phentermine (30 mg) 
with fenfluramine (40 mg), phentermine (30 mg) with fenfluramine (80 mg), and 
placebo. Phentermine produced effects that were similar to those of d-amphetamine, 
whereas fenfluramine produced different and apparently aversive effects (e.g., it 
increased measures of anxiety and confusion). Phentermine reduced the apparently 
aversive effects of fenfluramine when the two drugs were given together. These 
results suggest that the combination of phentermine and fenfluramine would have a 
low potential for abuse. 
 
 
2.9.7  Summary 
It is evident from the comparatively sparse literature on MDMA and driving that 
much more research is required in order to increase understanding of the impairing 
effects of this drug. In particular, most medical research has concentrated on the 
short-term effects of MDMA and little is known of its consequences following long-
term usage.  
 
Only a few countries have the technology to isolate new synthetic drugs from other 
substances in blood or urine samples and so data is lacking. For the present, the well-
established side-effects and widely-publicised MDMA-related deaths are suggestive 
that the drug is far from free of impairing effects.  
 
This is exacerbated by the fact that ecstasy tablets are often comprised of numerous, 
potentially toxic constituents, the combined effects of which are largely unknown; a 
problem which also arises from the fact that polydrug use is common amongst the 
dance culture.  
 
The contents of tablets keep changing in order to evade arrest as defined by the 1971 
United Nations Convention on Psychotropic Substances (it generally takes two or 
three years for new drugs to be added to the list). All precursors and other ingredients 
are available freely within the EU. Similarly, there is very little evidence concerning 
the specific effects of GHB, ketamine, PCP, fentanyl and abused diet drugs on driving 
abilities and in field studies they have not been frequently detected.  
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Given the known side-effects of these drugs however and especially given the 
perception- and cognition-altering effects of some of them, notably PCP and fentanyl, 
it is likely that they constitute a danger where driving is concerned.  
 
At present, much more experimental work needs to be carried out in order to elucidate 
the effects of all these drugs on mental and psychomotor performance. 
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Chapter Three 
Description of Drug Testing Procedures in Context of Driving in EU, 
Issues Raised by Testing, and Assessment of the Criteria that are 
Used or Proposed in Relation to the Scientific Evidence 
 
 
 
3.1 The Existing Situation in European Union Countries 
Parts of the following descriptions of drug-testing legislation in EU countries are 
based on work conducted by Dr Johan de Gier for the Institute for Human 
Psychopharmacology in The Netherlands in 1993. Since only eight countries were 
included in that study (Belgium, Denmark, France, Germany, Italy, Spain, The 
Netherlands and the United Kingdom), the present summary will also outline the 
situation in the remaining seven countries that are currently in the EU. All of the EU 
member states, including those originally covered by de Gier, were contacted for 
information on their drug-testing procedures. The information given below reflects 
the level of detail submitted by contacts in each of these countries. 
 
 
3.1.1  Belgium 
There are no specific criteria relating to different drugs (licit or illicit) or the extent of 
use in Belgium. Drivers can be penalised for driving under the influence of drugs as if 
alcohol had been used above the legal limit. However no indication is given of how to 
define the influence of drugs.  
 
Police may hold a person to have laboratory specimens of their blood taken if there is 
cause to suspect that they have committed an offence. Police can use a urine test on 
the roadside, but a blood test has to be used to determine the presence of drugs other 
than alcohol. 
 
Court decisions to convict a person of DUI are not influenced by police reports but by 
the findings of blood sample analyses carried out by experts. As de Gier (1993) noted, 
it is not clear how an offender is required to prove that he is no longer abusing drugs; 
this depends on the decision of the medical adviser.  
 
Package inserts produced by pharmaceutical companies must contain specific 
warnings about the effects on driving or operating machinery, as required by EU 
legislation. 
 
Belgium is currently considering a project of law which covers several illicit drugs 
including ecstasy and cannabis; it is unclear whether this law will pursue a zero limit 
or an impairment approach (Kruger et al, 1999).  
 
 
3.1.2 Denmark 
As is the case in most EU countries, police may hold a person to give bodily 
specimens if there is reason to suspect that they have committed an offence.  It is not 
clear under what circumstances the police will in fact do this.  
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In common with several EU countries, a driving licence may be refused to any person 
who is addicted to drugs, or who is a known alcohol abuser.  
 
Doctors have a strong influence on monitoring fitness to drive and are guided by 
governmental guidelines (although they do not cover the use of prescribed or illicit 
drugs ).  
 
Since 1983, all Scandinavian countries have a package label warning, a red triangle, 
which is portrayed on all 'especially hazardous' drugs. 
 
 
3.1.3 Austria 
In Austria, an individual driver can be tested for the presence of psychotropic drugs 
other than alcohol only if there is sufficient behavioural reason to do so.  
 
Where alcohol is concerned, every individual can be tested. Blood samples can only 
be screened for alcohol; only with the donors permission can tests be conducted to 
detect other drugs.  
 
As well as not allowing forcible blood testing, there is no urine testing under Austrian 
law. 
 
 
3.1.4 France 
Police may hold a person to apply breath alcohol analysis if there is strong reason to 
suspect him of having committed an offence. If more than drunkenness is suspected, 
the person may be taken for a medical examination in a psychiatric hospital, although 
it is not clear under what circumstances the police will decide to do this.  
 
Doctors decide on the need to have blood or urine samples taken. If a serious accident 
or offence has been committed, a 'Prefet' may order an examination by a Medical 
Commission.  
 
A driving licence may be refused to any person who is addicted to drugs, or who is a 
known alcohol abuser. A booklet was published in 1991 for drivers information and 
contains a list of all drugs available in France that could impair driving performance. 
 
 
3.1.5 Sweden 
Swedish police have the authority to stop any driver at any time and anywhere and 
request a breath sample as a screening test for the detection of alcohol. Drivers cannot 
refuse to provide a sample. If they do not give a breath sample, a blood sample will be 
taken anyway. As for other drugs, blood samples can only be taken in those cases 
where the police have reasonable suspicion that the driver is under the influence of a 
substance which is impairing driving performance.  
 
Sweden is likely to produce new legislation within six months which will probably 
include a zero tolerance limit for illegal drugs. 
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3.1.6 Germany 
Police may require a driver to give specimens if there is cause to suspect them of 
DUI. Experts may indicate positive evidence of the presence of given medicinal drugs 
in the blood to be the cause of the violation in a court situation, but this is considered 
to be a rare event in the experience of the German authorities (de Gier, 1993).  
 
Since August 1988, blood samples containing cannabis, heroin, morphine, cocaine, 
amphetamines and their analogues can result in a driver being arrested for a 
regulatory offence. Tests can be carried out even without the driver having committed 
an offence. Germany has adopted a zero-tolerance policy for drugged driving. 
Doctors must inform patients about the potential impairing effects of medication. 
 
 
3.1.7 Spain 
Spain has no specific legislation related to driving and drug abuse. Instead police and 
the civil guard may require a driver to give specimens if a driver appears to be 
endangering him/herself or other road users or if there is cause to suspect them of 
DUI. Experts may indicate positive evidence of the presence of given medicinal drugs 
in the blood to be the cause of the violation in a court situation, but this is considered 
to be a rare event in the experience of the Spanish authorities (de Gier, 1993).  
 
A driving licence may be refused to a known addict.  
 
Package inserts alert drivers to the possible impairing effects of medicines.  
 
 
3.1.8 Italy 
Police have powers similar to those in countries already mentioned. Urine samples 
can be screened for the presence of both licit and illicit drugs if there is clear reason to 
suspect a driver. Driving licences may be refused to any known addict or habitual 
alcohol abuser. There is no official list of drugs maintained by health authorities that 
could be used to require additional patient warning activities on the part of doctors 
and pharmacists (de Gier, 1993). 
 
 
3.1.9 Netherlands 
Police have powers similar to those in countries already mentioned. de Gier (1993) 
found that the Forensic Laboratory receives about 250 requests for blood sample 
analyses every year, one third for illicit drugs and two thirds for medicinal drugs.  
 
Published guidelines outline conditions in which a person is unfit to drive where 
medicinal drugs are concerned. However, the system does not take into account the 
differences between differing drugs and doses.  
 
After a general information campaign on the influence of drugs on driving, a 
questionnaire study revealed that 70 % of patients who were using a labelled drug still 
had not changed their behaviour towards driving (de Gier, 1993).  
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A graded level warning system for drugs which impair driving performance has been 
proposed by Dutch scientists. 
 
 
3.1.10 Ireland 
Members of the Garda Síochána or Irish police force may stop a driver suspected of 
DUI under the 1994 Traffic Act if there is sufficient cause to do so. They may then be 
taken to a Garda station and required to give a blood or urine sample if intoxicants 
other than alcohol (that is drugs) are suspected.  
 
In accordance with Road Traffic Legislation, the Medical Bureau of Road Safety 
arranges for the determination of the presence of drugs in the sample and this 
arrangement involves analyses being carried out by the State Laboratory.  
 
Medical evidence, although helpful in a court of law, is not essential in deciding 
whether or not a driver was unfit to drive as a result of drug ingestion.  
 
General package inserts inform the public as to the likely impairing effects of 
medication. 
 
 
3.1.11 United Kingdom 
Police have powers similar to those in countries previously mentioned. Several 
roadside screening devices have been tested in the UK.  
 
General package inserts inform the public as to the likely impairing effects of 
medication although no official list of drugs is maintained by health authorities that 
could be used to require additional patient warning activities by physicians and 
pharmacists. There are no specific leaflets on drugs and driving for patient 
information.  
 
The warning on drug labels affixed by pharmacists are not considered as being very 
effective, since patients don't see pharmacists as health care providers who can advise 
them. de Gier (1993) found that the implementation of a European warning system 
would be considered an important contribution to traffic safety and public health in 
the UK. 
 
 
3.1.12 Portugal 
Police have powers similar to those in countries already mentioned. Although it is 
illegal in Portugal to drive whilst under the influence of narcotics, stimulants or illicit 
substances, there are no drug testing procedures in use outside of standard sobriety 
tests for alcohol consumption.  
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3.1.13 Luxembourg 
Police have powers similar to those in countries previously mentioned. As things 
stand at present, Luxembourg does not have any drug testing procedures. However, if 
a driver has been stopped by police for erratic or unsafe driving they must submit 
themselves for a medical examination if asked to do so. 
 
 
3.1.14 Greece 
As in other EU countries, drivers suspected of DUI may be required to give a blood 
and/or urine sample for toxicological analysis. The central Anti-Drug Co-ordination 
Unit has recently suggested the implementation of drug testing procedures based on 
urine and blood analyses after fatal accidents. This proposal was made in the 
framework of the development of the Early Warning System in Greece and is under 
consideration by the Ministry of Public Order. 
 
 
3.1.15 Finland 
There are no legal limits for drugs and driving in Finland. A driver can be convicted 
for the intake of drugs if he/she is intoxicated to the extent that he/she may be 
dangerous to traffic safety. In order to identify drunken drivers in Finland, the police 
are authorised by law to submit drivers to the breath test even without any suspicion. 
If necessary, a blood and/or urine sample can be taken even against the will of the 
driver. A standardised roadside sobriety test is not yet in use in Finland. 
 
Alcohol and drug determinations of suspected driving under the influence of alcohol 
and/or drugs are centred in the National Public Health Institute (KTL) in Finland. 
Drug analysis is performed at the request of the police. Blood samples of all cases are 
analysed for ethanol. The urine samples in the suspected drug cases are screened for 
other drugs usually only if the alcohol concentration is below 1.2 %. If a urine sample 
is not available, drug screening in blood is performed. After screening for the drugs in 
urine, blood concentrations are measured in order to evaluate the effects of the drug 
on driving ability.   
 
Drugs that have potentially harmful effects on driving ability have warning labels on 
their packages. 
 
 
3.1.16  Summary 
Countries in the European Union have no laws defining illegal blood limits of illicit 
drugs or medicines. At present there is insufficient evidence to define safe levels 
where drugs other than alcohol are concerned. However it is common in the Union to 
withhold driving licences from individuals dependent on licit or illicit drugs which 
compromise driving abilities (Patel, 1995). 
 
All EU Member States have legal provisions for prohibiting (DUI of) psychotropic 
substances in addition to alcohol in their Traffic Codes. However there are no specific 
criteria related to the different types of drugs (licit or illicit) or the extent of usage.  
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There are substantial differences between countries in applying sample analysis for 
the determination of drug abuse and it is often unclear under what circumstances 
police officers will require a driver to give a sample. Blood sample analyses are 
conclusive in a court's decision on DUI in Belgium, the UK, Germany and Spain. In 
Denmark, The Netherlands, Germany and Italy urine samples may be taken when 
blood sampling is deemed unacceptable on medical grounds and in Italy urine 
samples must be taken in the presence of a doctor. Police in France may hold a driver 
for medical examination in a psychiatric hospital. 
 
de Gier (1993) concluded that, as regards identifying and checking driving under the 
influence of illicit or medicinal drugs, there is little police enforcement compared to 
that applied to alcohol related road safety problems in the EU.  It is probable that EU 
licensing authorities would require more conclusive experimental and field data on 
increased accident risk before more effective methods for identifying drug-impaired 
driving could be legislated for.  This would also be necessary before standardised 
dosage and duration instructions could be drawn up. 
 
de Gier (1993) also concluded that, since government campaigns are mainly focused 
on alcohol and driving, and seldom mention the detrimental effects of medicinal and 
illicit drugs upon driving, one can expect a minimal awareness of the problem of 
drugs and driving among the driving public. Therefore, where medicinal drugs are 
concerned, people must rely on general package inserts. Although a uniform EU 
warning symbol may be useful, it may also come to be ignored, as suggested by 
reaction to a similar warning system in The Netherlands. The European Unions 
Committee for Proprietary and Medicinal Products has in fact enforced, albeit slowly, 
a three-tier warning system for identifying the possible impairing effects of drugs. In 
general, in the case of prescribed drugs, the medical profession could be involved to a 
greater extent in spreading awareness about the role of drugs in driving impairment. 
 
 
3.2 Existing and Proposed Methods of Testing 
Generally, without the aid of actual sample-measuring tests, police officers have to 
rely on standard field sobriety tests (SFSTs) based on breath tests or blood tests for 
alcohol. These tests do have a good track record, but suffer from a fundamental lack 
of speed in administration and processing. In some parts of the USA police are trained 
as Drug Recognition Experts (DREs) and can evaluate an individual for drug 
consumption based on a series of behavioural tests (Crandon, 1997).  
 
Such tests involve (1) an initial breath test; (2) an interview; (3) a preliminary 
examination including having the person standing on one leg for 30 seconds, walking 
and turning tests, divided attention tests and a horizontal/vertical gaze nystagmus test; 
(4) dark room examination (including checks on pupil response); (5) vital signs 
examinations (blood pressure, temperature, etc.); (6) muscle rigidity examination; (7) 
examination of injection sites; (8) suspects' statements; (9) opinions of the evaluator 
are recorded; and (10) a toxicological examination for scientific confirmation.  
Ideally, the last step could be administered on-the-road with results produced on a 
time scale similar to or better than the initial breathalyser test, although the issue of 
fitness-to-drive would still have to be addressed. Such schemes are also under test in 
Germany and in Scotland. 
 
 58
Standard laboratory drug testing of biological fluids generally consists of 
immunoassay screening followed by gas chromatographic-mass spectrometric 
(GC/MS) confirmation conducted on a urine sample (Kintz et al, 1998). Newer 
methods using sweat or saliva samples are potentially preferable because they are 
virtually non-invasive, fast, and easy to execute by non-scientists (e.g. police 
officers). For them to be able to compete with standard laboratory techniques, such 
tests must have a high sensitivity and a high specificity in order to avoid false positive 
and negative results. Sherwood (1997) points out that at present in the UK, an initial 
test for alcohol only costs approximately £15, whereas a subsequent laboratory 
analysis for drugs costs around £350. A further necessity for the newer techniques is 
therefore that they are cost-effective. 
 
At present there are no roadside drug tests in regular usage, although several tests are 
now available including Triage, Ezscreen, Accupinch, Mach IV, Verdict, Biosign and 
I.D. Block (see Crouch et al, 1998)4. Drugwipe devices (Securetec, Ottobrun, 
Germany) have been developed which take a sweat specimen from the forehead, or 
armpit, and can be used with saliva also (drug traces are revealed by colour changes 
on the strip). The chemical test box uses antibodies to detect substances, and results 
are presented within approximately five minutes. If positive, drivers can be taken to a 
police station to give a blood or urine sample for confirmatory purposes. At present, a 
different device is required for different drugs, but the wipe can test for cannabis, 
amphetamines, MDMA, methadone, benzodiazepines, cocaine, barbiturates and 
opiates. There are also saliva-testing or "lollipop" technologies (Cozart Bioscience 
LTD, Oxfordshire) which give digital readouts from colour changes and these also 
can detect cannabis, amphetamines, MDMA, cocaine benzodiazepines and opiates. 
There is ongoing work concerned with establishing the sensitivity and specificity of 
many of these tests. 
 
'Drugwipe' has been experimentally tested by Kintz et al (1998). They tested six 
subjects after oral ingestion of 60mg codeine. They found that, with the exception of 
one female subject, Drugwipe exposed the codeine in the sweat samples. However the 
saliva Drugwipe caused too many 'false negatives' for the authors to consider it 
reliable. The authors could not explain the non-detection in the female subject, or the 
poor saliva testing results, but suggest that the volume taken of saliva may not have 
been great enough, some interfering substances may have been present, or the 
sampling time (10 seconds) was too short. Overall however, the results for the sweat 
Drugwipe were promising. 
 
An earlier use of saliva testing was conducted by Peel et al (1984). Fifty six saliva 
samples from 445 suspected drivers were analysed for the presence of cannabinoids, 
volatiles and benzodiazepines using the enzyme multiple immunoassay technique 
(EMIT) and confirmed by GC/MS. The authors concluded that the use of saliva was a 
potentially versatile non-invasive technique. More recently, the EMIT ETS system 
has been used to successfully screen for drugs using blood samples (Lillisunde et al, 
1996). They suggest that this method can be used when urine samples are unavailable, 
although urine is preferred since drug concentrations are usually higher and can be 
detected for longer in urine. However the use of blood samples may be more 
                                                 
4  Most of the tests referred to in this section are new or under development. We did not have access  
 to exact information regarding the sensitivity or specificity of these tests. 
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important with respect to the evaluation of driving performance related to the drug. 
Although the system is laboratory based, the through-time is about 50 samples per 
day, given three technicians working on the samples. 
 
A recent development which uses only three drops of urine for drug testing is the 
Syva Rapid Test assay (Behring Diagnostics Gmbh, Frankfurt). The test is a small 
hand-held device which displays easy-to-read results in five minutes. Negative 
outcomes are indicated when lines appear in both the test and control windows (a line 
in the control window only indicates a positive result). This test can detect THC, 
methamphetamine, opiates, amphetamines, phencyclidine, barbiturates, 
benzodiazepines, methadone and tricyclic antidepressants. It is currently available in 
the UK and Ireland, and will be available in Scandinavia, Spain and the U.S.A. as 
well as other countries (Labmedica, 1997). The simplicity of this procedure reduces 
the likelihood of human error. 
 
Several other urine sampling 'on the spot' tests have been developed. For example, 
Syva and Roche have individual tests for amphetamines, opiates and cannabinoids. 
Merck/BDH have a 7-substance screen in just the one test, and Tepnol Diagnostics 
have developed a test wherein individual test sticks join together into the required 
combination. However these still fall short of the breathalyser tests since they require 
a flat surface to work on, require several minutes to process substances, the reagents 
which are used often must be kept cooled and good light is necessary to determine 
colour/pattern changes (UK Parliamentary report, 1996). They can be used for initial 
screening purposes however, and compared to laboratory techniques they are much 
cheaper (£5 - £30). 
 
Buchan et al (1998) evaluated the accuracy, efficiency and cost-effectiveness of four 
on-site multi-analyite drug testing devices. 303 urine samples were tested with Triage 
(Biosite Diagnostics, U.S.A.), Abu-sign (Princeton BioMeditech, U.S.A.), OnTrack 
(Roche Diagnostic Systems, U.S.A.), and TesTcup ( Roche Diagnostic Systems, 
U.S.A.) and confirmed by GC/MS testing. Overall the authors concluded that all the 
tests worked well, however the Abu-sign and TesTcup devices were superior, largely 
because they eliminate the need for reagent mixing/handling. In contrast the OnTrack 
was the most cumbersome. For cannabis, Abu-sign showed 100% sensitivity whereas 
OnTrack showed the least sensitivity at 82.9%. The situation was similar for cocaine, 
but all tests showed 100% sensitivity for opiates. All kits also showed excellent 
specificity and performed well on negative predictive value measures (i.e. the 
probability that a negative result is a true negative). The highest false-negative rate 
was only 8% (TesTcup). 
 
OnTrack TesTcup and Abuscreen OnTrack were also tested by Crouch et al (1998) 
and compared to standard laboratory results (Abuscreen Online and GC/MS analysis). 
They found that TesTcup had virtually a 100% agreement with the laboratory tests 
when testing negative samples. For samples containing opiates and benzodiazepines 
the agreement rates were 100% and 98% respectively. Less agreement was found for 
THC however. OnTrack also had a 100% agreement when testing negative samples 
and samples containing opiates, although agreement was 91% for benzodiazepines. 
Again the least agreement was for samples containing THC. It was concluded that 
both on-site tests were effective and produced results comparable to laboratory tests. 
 
 60
Although some techniques have been examined which test hair samples, the 
consensus of opinion indicates that they are not reliably effective due to the 
inconsistent relationship between results and recent drug ingestion. 
 
 
3.3 Issues Involved in Testing for Drug Use 
Typically, Road Traffic Acts state that it is an offence to be in charge of a motor 
vehicle while "unfit to drive through drink or drugs." Although the acts give limits for 
alcohol, no limits are given for drugs. This obviously makes it difficult for police 
forces to arrest individuals suspected of driving whilst under the influence of drugs. 
Even if this is possible, in order for a conviction to be established, expensive and 
complex forensic evidence has to be produced. This in turn makes the police hesitant 
to arrest in the first place. Unlike the case with alcohol, it is often difficult to tell by 
external behaviour alone that an individual has been taking drugs. Indeed they may 
appear coherent and confident. This may be true even in the case of hallucinogenic 
drugs.  
 
The subtle indications of drug use such as dilated pupils or increased heart rate may 
be especially difficult to spot by the untrained observer. Again, unlike the case with 
alcohol, it is difficult to establish a relationship between dose and effect. Due to the 
variable action of many drugs, the impairment obvious to a police officer may not be 
evident at all by the time a drug test is conducted. Unfortunately, it is virtually 
impossible to decide on a 'legal limit' for drugs, as some have suggested, since risk 
curves cannot be reliably calculated. It may therefore be more practical to carry out 
behavioural impairment tests. There is the additional problem that any legislation 
would have to legislate for drugs which can be used both legally and illegally. 
 
One possible solution to this is to give police forces expert training in roadside 
behavioural evaluation of suspects. Such a scheme has been established in the United 
States (UK Parliamentary Office, 1996), and is relatively inexpensive to set up. 
Another approach to the problem is to establish roadside drug testing in a similar 
manner as the prevalent breathalyser tests, only using immunological assays, some of 
which were described above. This in itself suffers from several practical and logistical 
constraints, most notably that privacy needs to be ensured in order for the requisite 
urine sample to be given and thus some type of portable toilet/laboratory is necessary. 
However, the scheme is inexpensive compared to the cost of sending samples for 
professional analysis.  
 
Evidently the ideal would be the development and use of techniques which can deal in 
real-time with non-invasive samples. It should be emphasised however, that merely 
demonstrating the existence of a drug trace in the body is not sufficient proof of being 
unfit to drive or that the drug was responsible for impaired psychomotor behaviour. 
Only if unfitness was proved, for example via a standard field sobriety test, could a 
conviction be secured. 
 
 
3.3.1  Mandatory drug testing 
It has been suggested on occasion that mandatory drug testing should occur for 
employees or individuals whose potential drug abuse could affect public safety, 
including highway safety. However this concept has sometimes been criticised for 
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amounting to little more than a "witch hunt" by those whom it may affect, who claim 
that it is not only intrusive, but also unnecessary and ineffective (Sutherland, 1992).  
 
Such a situation has arisen in Canada in the multinational Imperial Oil Limited where 
it is compulsory for all new employees to have a urine sample screened. This scheme 
was attacked by the Canadian Civil Liberties Association under the Ontario Human 
Rights Code. The main criticism apart from the inherent privacy infringements was 
the possibility that workers taking legal prescription medicines could be discriminated 
against.  
 
Sutherland (1992) also notes that the scheme may have ruled out the possibility of 
recovery for drug addicts and may have consequently caused a resumption of 
addictive behaviour. As the strategy stands, employees are screened for alcohol, 
cannabis, cocaine, amphetamines, opiates and phencyclidine hydrochloride; all 
urinalyses are confirmed by gas chromatography/mass spectrometry. 
 
British Rail, London Buses, London Underground, BP, Shell and Texaco all have 
drug and alcohol testing procedures. The Confederation of British Industry (CBI) 
estimates that 8% of its members have formal drug-testing policies (Parliamentary 
Office of Science and Technology, 1996). The International Transport and Workers 
Federation (ITF) believes that the "targeting of transport workers is the result of a 
widespread, but totally unproven, belief that drug and/or alcohol abuse is a major 
factor in transport accidents (Bargaining Report, 1993). In addition to the 
infringement of 'civil liberties' involved, they also believe that testing can only reveal 
whether the individual has consumed a substance not whether they are a habitual 
consumer or addict. There are evident concerns that victimisation, scapegoating and 
harassment may ensue. 
 
Types of testing include:  
(1) Voluntary testing  despite the positive aspects of this, it still needs to be ensured 
that no negative consequences follow a refusal.  
 
(2) Pre-employment screening  it needs to be ensured that discrimination does not 
occur and that medicine users and non-addicts can still be employed.  
 
(3) Random testing (one-off probe or regular intervals)  reasonable grounds for this 
need to be established.  
 
(4) Regular testing (of whole groups in 'safety sensitive' positions).  
 
(5) 'For-cause' testing (of suspected individuals)  again, just cause must be 
established to prevent harassment, and the judgement should be based on more 
than one individual's assessment.  
 
(6) Post-accident testing.  
 
(7) Post-treatment testing  it is often suggested that random testing will not deter 
those dependent on drugs and that drug-related health promotion activities are 
preferable, especially activities such as performance appraisal which is more 
consistent with industrial relations practice (Bargaining Report, 1993). 
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3.3.2  Warning Labels 
A recent Automobile Association report (Sherwood, 1997) notes that in the case of 
prescribed medication, where warnings on bottles and so forth are concerned, there is 
usually little acknowledgement that impairing side-effects generally wear off. 
However given the 'small-print' nature of most warnings it is likely that users may 
ignore them, or if it is stronger, may not take the medicine and thus unwittingly 
become a road hazard. There should perhaps be a differentiation between warnings 
for immediate effects and warnings for longer term effects.  
 
Some countries use a warning symbol on bottles, but there is a risk that if this were 
widely used it would become ignored. Given that there are many 'newer' drugs which 
have less impairing side-effects, doctors should perhaps prescribe these in preference 
to the older drugs, although the newer ones may be more expensive (to produce 
and/or use). If an individual has taken medicinal drugs and subsequently committed a 
crime (such as DUID), the drugs may actually exonerate them from the crime. In 
addition, a pre-existing condition such as epilepsy may have played a role. Issues such 
as the instructions the person was given by their GP/pharmacist, the bottle instructions 
and the dosage are important because the person may have committed the crime 
unwittingly - or may have combined drugs, or taken them at the wrong time or 
dosage. However, Samuels (1987) admits that drugs can never really be a defence. 
 
 
3.4 The Possibility of Registering New Drugs 
Where registration for new drugs intended for future patient use is concerned, 
O'Hanlon et al (1986) have noted that it is important that some type of drug test is 
implemented because the effect of having nothing is to potentially cause loss of life, 
whereas the cost of having some type of test is likely to be counted in monetary terms 
only. The results of a test or battery of tests could be used in several ways: (1) To 
completely prohibit driving for the drugs' users (either for a specific time period 
measured from the time of last ingestion, or at the beginning of a regular 
administration period, or both); (2) To restrict the type of driving (e.g. night driving) 
during all or part of the drugs' use; (3) To issue specific warnings regarding the 
potential impairing effects of the drug by doctors or pharmacists; and (4) To require 
drug manufacturers to give explicit warning information on their products. 
 
O'Hanlon et al (1986) further suggest that one test developed by the Traffic Research 
Centre may be a useful start. It consists of an actual driving test which is taken after 
ingestion of a drug, in which subjects have to maintain a constant speed (95km/hour) 
and steady lateral position between lanes on a 100km circuit in normal traffic. The 
main test measurement is the standard deviation of lateral position (SDLP), although 
whether this is a valid indicator of driving ability has been disputed. The authors 
admit that the test could not be applied during preliminary stages of drug screening, 
but may be useful until such a time as highly effective on-the-road tests can be used. 
 
 
3.5 Towards a Unified Approach 
Each country in the European Union has a different approach to drug testing. Based 
on a survey of 270 European laboratories, the Toxicology Experts Working Group 
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drew up a list of recommendations to try and establish uniformity amongst the 
different countries (de la Torre et al, 1997).  
 
As regards sample handling and chain of custody it was proposed that (a) Sample 
collection procedures should ensure privacy for the donor; (b) A split sample is 
preferable (A and B aliquots) to permit dual analysis; (c) Although it is preferable for 
only the one laboratory to carry out all of the necessary tests, it is permissible to 
exchange samples between co-ordinated laboratories provided that chain of custody 
procedures are strictly adhered to; (d) All stages of analysis, including transportation, 
must be well-documented; (e) Chain of custody procedures must be audited; and (f) 
Samples not complying with the above regulations should be rejected. If all these 
proposals were put into practice, the preservation of the sample's integrity, test 
validity, and the maintenance of confidentiality should be ensured. 
 
Regarding cut-off values it was proposed that (a) Cut-off values should be formally 
stated. This should limit the current confusion which exists regarding cut-off values 
for the identification of specific substances; (b) The following cut-off values were 
recommended for Workplace Drug Testing: Opiates 300mcg/l (confirmation, total 
morphine, 200mcg/l); Cocaine metabolites 300 mcg/l (confirmation, 
benzoylecgonine, 150mcg/l); Amphetamines 300 mcg/l (confirmation, amphetamine, 
200mcg/l; methamphetamine, 200mcg/l; MDMA, 200mcg/l; MDA, 200mcg/l; 
MDEA, 200mcg/l); Cannabinoids 50mcg/l (confirmation, THC, 15mcg/l). 
 
Concerning analytical methodology, it was proposed that (a) Validated immunoassays 
should be used for initial screening purposes; (b) Chromatographic methods coupled 
to mass spectrometry should be used for the subsequent identification of specific 
substances; (c) the quantification of drugs in biological fluids was recommended, and 
when mass spectrometry is used, isotopically labelled internal standards are 
preferable; (d) reference materials must be available in all laboratories (the survey had 
shown that this improved the performance of laboratories); (e) European regulations 
should facilitate the availability of drugs especially as low-concentration solutions; 
and (f) an organisation should be established with responsibility for providing 
reference materials, for holding test samples for educational and training purposes, 
and for devising methods of obtaining compounds not commercially available as 
reference substances. 
 
The survey found that there were clear misunderstandings about terms such as 'cut-
off' and the setting up of chromatographic techniques. To counter this, the following 
proposals were made regarding the educational requirements of all laboratory 
personnel, including directors: (a) minimum educational requirements for all relevant 
personnel should be defined; (b) educational updating should be required for all 
personnel; and (c) interpretation of results should be handled by the testing laboratory. 
 
The survey also found that not enough laboratories were taking part in some form of 
External Quality Assessment Programme on Drugs of Abuse Testing (EQAPDAT) or 
Proficiency Testing Programmes (PTPs). These are important for laboratories to be 
accredited. Accordingly it was proposed that (a) laboratories should be accredited to 
EN45001 ISO Guide 25; (b) the other recommendations outlined above should form 
the basis for tailoring the EN45001 specifically for European drug testing; (c) 
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laboratories should take part in a EQAPDAT; and (d) existing EQAPDATs should 
collaborate on the establishment of homogeneous operation criteria. 
 
Proposals for workplace testing also concur with several of these points (Bargaining 
Report, 1993): 
(1)  Written consent must be obtained. 
(2)  Blood and urine samples should be acquired in the presence of an independent 
witness. 
(3)  Chain of custody procedures should be adhered to avoid contamination of, or 
interference with, the samples. 
(4)  Split samples should be used to increase reliability. 
(5)  Testing should be carried out by independent experts who can interpret the 
results. In addition, only government-certified laboratories should be used. 
(6)  GC/MS should be used for initial and confirmatory screening. 
(7)  Results should be interpreted to discriminate between medicinal use and illicit 
use. 
(8)  A medical review officer should be used to arbitrate where a result is challenged. 
(9)  Police should only be involved when a serious case has occurred. 
(10) All records should be confidential but available to the person concerned. 
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                                APPENDIX:   Expert Workshop – Programme 
 
 
 
The Health Research Board 
in collaboration with the 
Transport Policy Research Institute UCD 
 
 
Study involving a 
Literature Review on the Relation between 
Drug Use, Impaired Driving and Traffic Accidents 
on behalf of the EMCDDA, Lisbon 
 
 
Workshop involving Invited Irish-based Experts 
Dublin, 10 November 1998 
 
 
AGENDA 
 
1 Welcome by the Director of the Health Research Board 
Dr Ruth Barrington 
 
2 Chairmans Introduction 
 Professor Jim Crowley, UCD 
 
3 Background to the Project 
 Ros Moran, HRB 
 
4 Brief Tour de Table 
 
5 Introduction to Work Package #1 (Methodological Issues) 
 Colin Gemmell 
 
6 Discussion on Work Package #1 
 
7 Work Packages #2 (Experimental/Laboratory Evidence) and #3 (Field Studies 
of the relationship between Drug Use/Abuse and Traffic Accidents) 
 Colin Gemmell 
 
8 Discussion on Work Packages #1 and #2 
 
9 Work Package #4 (Procedures for Testing incl Legal and other Issues) 
 Colin Gemmell 
 
10 General Discussion 
All Participants 
 
11  Summary and Conclusion 
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